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Skeletal muscle atrophy is characterized by depressed cellular energetics, 
increased rates of protein degradation, contractile deficits and loss of muscle mass. A 
potential regulator of these impairments is the metabolic enzyme AMP Deaminase 3, 
which is highly upregulated during most if not all types of atrophy. The goals of the 
present dissertation were: 1) to investigate the role of AMPD3 on energetics and 
contractile characteristics of skeletal muscle during atrophy and 2) to determine the 
effects of AMPD3 in muscle cells on adenine nucleotide content and protein 
degradation. 
AMPD3 was knocked down by electroporation of shRNA plasmids into mouse 
soleus muscle during denervation-induced atrophy. One week later, muscles were 
removed, electrically stimulated, and contractile function measured. Muscle 
homogenates were analyzed by UPLC and western blot. Denervation increased AMPD3 
protein expression by 67%, while knockdown reduced AMPD3 by 60%. Knockdown of 
AMPD3 increased half relaxation times in both innervated and denervated muscles 
 
 
during tetanic and high intensity fatiguing contractions. Neither low intensity contractions 
nor overexpression of AMPD3 in non-atrophying muscles altered half relaxation time. 
To determine the effects of AMPD3 on protein degradation, AMPD3 was 
overexpressed by adenovirus in C2C12 myotubes. Adenine nucleotides, protein 
degradation rate, and indices of the major protein degradative pathways were 
measured. Overexpression of AMPD3 resulted in a 40% loss of ATP and an increase in 
IMP. Protein degradation rate was 38% greater while protein synthesis was unchanged, 
which resulted in a net loss of protein and myotube atrophy. Surprisingly, the autophagy 
activator ULK1 and apparent autophagic flux were unchanged. Further, proteasome 
subunit contents and in-vitro proteasome activity were similarly unchanged. However, 
consistent with greater protein degradation, total ubiquitinated conjugates decreased.  
The increase in half relaxation time with AMPD3 knockdown is consistent with 
the role of AMPD in preserving the free energy of ATP hydrolysis and SERCA function. 
Overexpression of AMPD3 also resulted in a loss of adenine nucleotides and 
acceleration of protein degradation, suggesting that a fall in ATP activates proteasomal 
degradation in-vivo. These exciting findings identify AMPD3 as a novel regulator of 
skeletal muscle performance and protein degradation during atrophy.  
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Chapter One 
Introduction 
 Skeletal muscle atrophy, loss of muscle mass, is a debilitating condition because 
those who suffer from it are limited in activities of daily living (26), have decreased 
quality of life (149), and increased risk of all-cause mortality (4, 94, 118, 144). Because 
muscle has critical roles in locomotion, respiration, and whole body metabolism, 
maintaining muscle mass can contribute to many aspects of improved quality of life. 
Most notably, the loss of muscle mass results in a loss of contractile filaments (27, 28, 
153), reduced strength (75, 146), and lower power (148). Clinically, atrophy is often 
referred to as cachexia, the involuntary loss of muscle mass, and is often associated 
with wasting states such as cancer and cardiac heart failure. Additionally, atrophy can 
be referred to as sarcopenia, the age related loss of muscle mass.  
 The loss of muscle mass is indeed a major concern of atrophy; however, loss of 
mass alone does not explain all the negative effects of atrophy. For example, increased 
fatigue (160), loss of mitochondrial content (108, 156), disrupted energetics (29, 33), 
reduced specific force (123, 131), and impaired contractile kinetics (53, 116, 123) are all 
observed during atrophy but are not solely a result of the loss of mass. Therefore, any 
treatment designed to address any of these issues or the loss of mass may alleviate 
some of the burden of atrophy. There is a lack of pharmacological treatments for 
atrophy and only exercise has been shown to be an effective treatment for atrophy (51). 
For example strength/resistance training increases muscle mass (131), force (131, 
148), and power (148) in conditions of atrophy. Additionally, endurance training can 
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improve mitochondrial content (63, 68), prevent loss of mass during atrophy (63, 64), 
and normalize the adenylate energy charge and ATP levels (33) in atrophying muscle.    
 Skeletal muscle atrophy is often comorbid with other disease and injury states 
such as cancer, chronic obstructive pulmonary disease (COPD), diabetes, renal failure, 
and sepsis as well as with disuse, starvation, and paralysis. The presence of these 
comorbidities makes exercise, the only known effective treatment of atrophy, difficult or 
impractical for the large number of people who suffer from atrophy. There are an 
estimated 5 million people in the US alone that suffer from severe muscle wasting or 
cachexia (101), 7-14 million people who suffer sarcopenia-related disability in the US 
and EU (51). The estimated cost of managing sarcopenia-related disability is $18.5 
billion in the US alone (74). In Japan it is estimated that 8.2% of men and 6.8% of 
women suffer from sarcopenia (162). Therefore, the discovery of new targets to treat 
atrophy is of great importance in order to improve quality of life, relieve suffering, and 
improve outcomes of disease. Treatment of atrophy may allow for more effective or 
more aggressive treatment of the underlying disease.  
 
Reduced Muscle Function/Performance 
 The reduced performance of the muscle during atrophy is a major impediment to 
the quality of life for those who suffer from atrophy. For example, the loss of muscle 
mass contributes to an increased fear of falling, decreased mobility, and decreased 
muscle performance (149). The mechanisms behind the decreased of muscle 
performance can begin to be unfolded by an examination of muscle contractile 
characteristics. There are several contractile characteristics of the muscle elicited by 
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both twitch (a single depolarization of the muscle) and tetanic (multiple depolarizations 
which summate and fuse the muscle) contractions, which become impaired when the 
muscle atrophies. Maximal force measurements such as absolute force (mN or g) or 
specific force (N/g or mN/cm2) are reduced. The fatigability or endurance capacity of 
muscle is also affected by atrophy. This is often demonstrated over a series of repeated 
contractions where the atrophied muscle is not able to maintain the same percentage of 
initial force output as a control muscle. Also time dependent variables such as time to 
peak force, rate of force development, and rate of relaxation show impairments during 
atrophy. All of these factors individually diminish muscle performance but when 
compounded together can severely reduce quality of life.  
 Maximal Force. The loss of maximal force or strength has been well documented 
in humans under several atrophic conditions such as bed rest (8, 148), immobilization 
(71), cancer cachexia (157), COPD (9, 31), and diabetes (10). Additionally, loss of force 
has been seen in many rodent models of atrophy. For example, after two weeks of 
denervation (severing of the sciatic nerve) in mice, the extensor digitorum longus (EDL) 
lost about 20% of its tetanic force production while the soleus lost about 40% (85). 
Twitch tension is reduced to 55% of control after 14 days and down to 21% of control 
after 42 days of denervation atrophy in rats (160). In mice with cancer cachexia, tetanic 
force is reduced by 25% and 30% in the soleus and EDL respectively (123). The 
reduction in maximal absolute force during atrophy can be largely attributed to the loss 
of muscle mass or fiber cross sectional area. However, some loss of force cannot be 
explained purely by the loss of muscle mass, as evidenced by reduced specific force 
during atrophy.  
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 Specific force, the force normalized to weight or cross sectional area of the 
muscle, can indicate whether other factors besides muscle mass are contributing to 
force production. A reduced specific force has been observed in mouse models of 
atrophy including denervation (2, 48, 76), hind limb unloading (131), and in cancer 
cachexia (123). While the specific mechanisms that account for this reduction in specific 
force are not known, it appears that the reduction in the number of available actin and 
myosin cross bridges is not a the only cause (48). A reduction in the specific force 
during atrophy indicates that the observed reduction in maximal tetanic force was due to 
more than just the loss of mass and may be explained by other factors such as 
energetics. For example, accumulation of metabolic products of ATP hydrolysis can 
influence force and power output of the muscle independently of changes in muscle 
mass. Accumulations of ADP have been shown to slow the rate of cross bridge cycling 
(30) and increased [Pi] can reduce peak force (37, 105).  
 Fatigue. The loss of endurance capacity is a common but less appreciated 
component of skeletal muscle atrophy. In humans, following 20 days of unilateral lower 
limb suspension (ULLS) there are marked decrements in endurance performance in the 
muscle. These participants experienced an average 11% decrease in VO2peak during an 
exhaustive one-legged cycling test (136) when compared to the ambulatory limb. 
Additionally, the suspended limb reached exhaustion 10% quicker than the ambulatory 
limb (3). Patients with atrophy from diabetic neuropathy also exhibited increased 
fatigability.  During a single maximal voluntary isometric contraction, force production 
dropped 21% more rapidly in atrophying muscles than in healthy matched controls (3). 
In a mouse model of cancer cachexia, the soleus muscle lost force production more 
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rapidly and dropped to a lower percentage of initial force than a healthy control during a 
10 minute fatigue protocol (123). Additionally, in disuse models of atrophy such as 
denervation and hind limb unloading fatigue is also accelerated in mouse soleus (92) 
and in rats (53, 131, 160). The increase in fatigability during atrophy is a common 
component and can be dissociated from the loss of muscle mass and maximal force.   
 A likely factor in the increase in fatigability during atrophy is a reduction in 
mitochondrial content (14, 108) and function (29, 156). During atrophy mitochondria are 
lost at a greater rate than muscle mass, resulting in a lower mitochondrial content for a 
given volume of muscle (14). Furthermore, the function of the remaining mitochondria is 
impaired as demonstrated by decreased maximal ADP-stimulated state 3 respiration. 
This has been demonstrated following 3 and 7 days of hind limb unloading (18), 14 days 
of immobilization (98), and 7 days of denervation (106). The reduction in mitochondrial 
content and maximal respiration during atrophy contributes to the reduced maximal rate 
of ATP synthesis (29, 140). Additionally, at submaximal workloads, a smaller 
mitochondrial content requires a larger increase in [ADP] to elicit a given increase in 
mitochondrial ATP synthesis (41). As a consequence, the muscle becomes more 
dependent on anaerobic ATP synthesis pathways which results in more rapid fatigue.  
 Contraction Kinetics. The kinetics of contraction are slower during atrophy. For 
example, the half relaxation time (time required after stimulation for force to drop to half 
of maximal) is longer during denervation atrophy and cancer cachexia (2, 53, 123, 158, 
160). The relaxation of the muscle is highly dependent on the ability of the 
sarcoendoplasmic reticulum calcium ATPase (SERCA) pump to re-sequester Ca2+ into 
the sarcoendoplasmic reticulum (SR). A slower relaxation time can be due to a change 
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in the composition of the SERCA isoforms or to a decrease in the activity of SERCA. 
Ca2+clearance from the sarcoplasm was severely impaired in the flexor digitorum brevis 
(FDB) muscles of hind limb unloaded rats (159) as well as Ca2+uptake by the SR 
following immobilization (146) suggesting that SERCA activity might be reduced during 
disuse atrophy. Changes in the composition of the SERCA pump isoforms during 
atrophy depends on the muscle type and model of atrophy. For example, a reduction in 
the content of SERCA1 (fast type) was seen in denervation in soleus muscle of rats 
although no change in SERCA2a (slow type) was observed (143). This isoform shift 
would be expected to result in a slower rate of Ca2+ re-sequestration and hence an 
increase in relaxation time. However, in contrast, there was an increase in both 
SERCA1 and SERCA2a in the EDL in a cancer cachexia model of atrophy (46), which 
may increase the rate of Ca2+ uptake and shorter relaxation time. While the exact 
mechanisms of slowed relaxation during atrophy are not known, the impairment itself 
may increase the energy burden for each contraction. During the relaxation phase, force 
production begins to drop as available myosin binding sites on the actin filaments are 
covered by tropomyosin. However, this process is not instantaneous, and ATP is still 
being consumed by the myosin ATPases through the relaxation phase, albeit at a 
reducing rate. The more rapidly Ca2+ can be re-sequestered into the SR, the more 
rapidly the myosin binding sites are covered and ATP usage by the myosin ATPase will 
decrease. Therefore, a slower relaxation time leads to more ATP consumption per 
contraction. 
 The time taken to reach peak force is also increased during both disuse and 
systemic atrophy (53, 123, 158). An increase in the time to peak force increases the 
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denominator of the power calculation (force x distance/time), and results in a reduced 
power output. Loss of power severely reduces performance of the muscle and 
increases risks for injury, especially for the elderly.  For example, lower muscle power 
(measured by chair stand) is an independent predictor of falls and potential fractures in 
the elderly (103). The increase in time to peak force during atrophy may be explained by 
a change in the fiber type distribution of the muscle. Type II fibers have a shorter time to 
peak force and, thereby, are more powerful than type I fibers. A reduction of type II 
fibers and/or an increase in type I fibers would reduce the power output of the whole 
muscle. However, shifts in fiber type during atrophy are not the same between systemic 
and disuse types of atrophy. 
 There are clear shifts in fiber type during atrophy (38); however, these shifts are 
not the same between species, strains, muscles, or models of atrophy (25). In general 
during systemic atrophy conditions there is a shift in muscle fiber type from fast to slow 
fibers. For example, with glucocorticoid administration there is a shift from type IIb to 
type IIa in the masseter muscle (154). Conversely, there is an opposite shift from slow 
to fast fibers in disuse atrophy. In denervation-induced atrophy there is a loss of type I 
fibers in the rat soleus and an increase in type IIa fibers as early as 7 days post 
denervation but not earlier (70). However, despite direction of the fiber type shift, the 
contractile kinetics are impaired. It then follows that shifts in the fiber type distribution of 
muscle during atrophy do not adequately explain the increase in time-to-peak force.  
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Energetic Disruption During Atrophy 
 One possible explanation of impaired contractile characteristics may be a 
depressed energetic profile. For example, reduced [ATP] content has been reported in 
denervation (92) cancer cachexia (33, 46) and spinal cord contusion (140). Additionally, 
increased [ADP] (110), a reduced free energy of ATP hydrolysis (ΔGATP) (29, 42, 54, 77, 
110, 140), and a loss of phosphocreatine (110, 140) and creatine (140) have been 
observed during atrophy. These energetic deficits are found in healthy, albeit 
atrophying, muscles which have reached a new steady-state phenotype with depressed 
energetics. Furthermore, a number of the contractile characteristics have been shown to 
be sensitive to perturbations in energetics. For example, muscle relaxation is slower in 
the presence of increased [ADP] (56). Additionally, high levels of [ADP] can slow cross 
bridge cycling, by preventing the dissociation of the myosin head from the actin filament, 
and thereby reduces the rate of force development (30). Elevated levels of [Pi] have 
been shown to reduce the peak force and power in skinned fibers (37, 105), likely 
because elevated Pi increases the time the cross bridge cycle spends in the low/no 
force phase of AM • ADP • Pi (62, 114). Taken together, it is reasonable to suspect that 
energetics may play a factor in some of the contractile impairments observed during 
atrophy. 
 In healthy muscle, the adenine nucleotide pool size is tightly regulated. The 
equilibrium reaction of the creatine kinase enzyme1 buffers reductions in [ATP] by 
consuming creatine phosphate (CP) to phosphorylate ADP and form ATP. Additionally,  
(1) ADP + CP → ATP + Creatine 
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the adenylate kinase enzyme2 (AK), another equilibrium reaction, limits accumulation of 
ADP by consuming two ADP molecules to form one ATP and one AMP. Furthermore, 
(2) ADP + ADP → ATP + AMP 
AMP deaminase3 (AMPD) will limit AMP accumulation by degrading AMP to IMP, 
(3) AMP + H2O → IMP + NH3 
displacing the equilibrium of the adenylate kinase reaction toward ATP production. All 
three of these reactions help to maintain the ΔGATP
4, where ΔG°ATP equals -30.5 kJ/mol  
(4) ΔGATP = ΔG°ATP + RTln([ADP] • [Pi]/[ATP]) 
(34) during perturbations in energy demand. At rest the ΔGATP is maintained at 
approximately -65 kJ/mol and during intense exercise the ΔGATP can decline to -54 
kJ/mol (155) in submaximal and -51 kJ/mol (56) in near maximal exercise.  
 A collapse of the ΔGATP is catastrophic to any living organism and is therefore 
tightly regulated. Even small reductions in the ΔGATP, on the order of 5 kJ/mol, have 
been shown to inhibit activities of key ATPases. For example, the Na/K ATPase activity 
is reduced and directionality can even be reversed at a reduced ΔGATP (52, 107). 
Likewise, under resting conditions the SERCA pump requires a large portion of the 
maximal yield of the ΔGATP in order to maintain the 1:10,000 Ca
2+ gradient across the 
sarcoendoplasmic reticulum membrane (21, 59). Chen et al. observed in cardiac muscle 
the free energy requirement of the SERCA was -49.5 kJ/mol (21). Accumulation of ADP 
during exercise can reduce the ΔGATP and compromise the function of the SERCA 
pump. Reduced activity of the SERCA pump would decrease the rate of Ca2+ clearance 
from the sarcoplasm and would prolong tension development, or in other words, slow 
muscle relaxation. Indeed Dawson et al. observed increased relaxation times when the 
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ΔGATP was depressed by 15-20 kJ/mol in contracting muscle (35). If the ΔGATP were to 
drop far enough (to approx. -41 kJ/mol), reversal of the SERCA pump could expel Ca2+ 
into the sarcoplasm, resulting in rigor mortis and eventual death of the myofiber. 
Therefore, preservation of the ΔGATP during high energy demands is of utmost 
importance to the survival of muscle and organism. 
 It is clear that the function of the muscle is dramatically compromised during 
atrophy (reduced force, specific force, increased fatigability, slower contractile kinetics, 
and disrupted energetics). Although the loss of muscle mass can account for some of 
the contractile impairments, such as loss of maximal force, it cannot account for many 
others (fatigue resistance, specific force, time to peak force, half relaxation time). 
Energetics seemingly plays a role in some of these characteristics. Exercise, the only 
effective treatment of atrophy, improves the energetic profile (adenylate energy charge, 
[ATP], etc.) in atrophying muscle (33), however it is unknown if improvement of the 
energetic profile itself can improve muscle health and function during atrophy.  
 
Loss of Muscle Mass 
 While there are many functional changes to the muscle during atrophy, as 
described above, the loss of protein and muscle mass is also of great concern. 
Preventing or limiting atrophy and/or increasing muscle mass may be beneficial for 
many who suffer from chronic disease. In a study of patients with chronic heart failure, 
those who also exhibited cachexia had a mortality rate of 50% within 18 months of 
follow-up compared to just 7% of those who did not exhibit cachexia (4). Skeletal 
muscle mass is also a valid independent predictor of all-cause mortality (118, 144). 
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Because atrophy is often comorbid with other chronic disease, treatment or prevention 
of muscle mass loss can allow for more effective or direct treatment of the underlying 
disease and help improve outcomes. 
 Skeletal muscle mass in adults is largely controlled by the rates of protein 
synthesis and protein degradation. When the balance between protein synthesis and 
protein degradation is shifted toward degradation, there is a net loss of protein and 
muscle will atrophy. There are two main pathways by which proteins are degraded, the 
ubiquitin-proteasome and the autophagy-lysosome system. It is widely recognized that 
both the ubiquitin-proteasome and autophagy-lysosome are upregulated during skeletal 
muscle atrophy (17, 81, 90, 106, 163), and make significant contributions to the loss of 
muscle mass. However, there are some who argue that it is a reduction in protein 
synthesis and not an acceleration of protein degradation that leads to atrophy (36, 121). 
This balance between protein degradation and synthesis is model specific and may 
differ between humans and rodents. For example, in denervation atrophy protein 
synthesis has been shown to increase (115). Regardless, the balance between protein 
synthesis and degradation is critical to maintaining healthy muscle content and 
treatments that target either may improve outcomes of disease. 
 The initial loss of muscle mass can occur rapidly as the rate of protein 
degradation is accelerated. For example, after just 24 hours of fasting in mice, the rate 
of protein degradation is increased 49% (161) and by 48 hours 14% of muscle weight 
can be lost (72). Additionally, 18-69 hours of mechanical ventilation was associated with 
a striking 50% reduction in fiber cross sectional area in the diaphragm (83). After an 
initial increase in protein degradation in response to the atrophy stimulus, the rate slows 
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until a new steady state is reached and further loss of muscle mass is minimal (130, 
160). Early treatment of atrophy is therefore critical to thwart excessive loss of muscle 
mass.   
 
AMPD3, a Potential Target for the Treatment of Atrophy 
 The signaling events that initiate muscle atrophy have received much attention in 
the past decade (81, 130, 134, 163). However, much still remains unknown, particularly 
with regards to how energetics may contribute to the activation of atrophy. It has been 
previously demonstrated that the disruption of the mitochondrial network can initiate 
atrophy (125), which suggests that impaired energetics may contribute to muscle 
atrophy. Furthermore, impaired energetics, whether it be lower [ATP] (46, 92, 140), 
increased [ADP] (110), decreased [CP] (110, 140) , or reduced ΔGATP (29, 42, 54, 77, 
110, 140) has been observed in many atrophy conditions. The adenine nucleotides, and 
energetics in general, are known to be involved in several signaling mechanisms. For 
example, the AMP activated protein kinase (AMPK) is activated by AMP and is involved 
in several signaling cascades that regulate muscle mass (133). It is currently unknown if 
disrupted energetics can be an initiating event of atrophy or if it is a response to 
atrophy.  
 While there are several potential regulators of energetics only some are 
differentially expressed during most atrophy conditions. The atrophy process is 
regulated, at least in part, by a coordinated transcriptional program of atrophy related 
genes (atrogenes). The atrogenes consist of approximately 130 genes that are up or 
down regulated during several types of atrophy such as cancer cachexia, fasting, 
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chronic renal failure, diabetes, and denervation (81, 130), and potentially all types of 
atrophy. One of the most highly induced atrogenes (up to 100 fold) is AMP Deaminase 
isoform 3 (AMPD3) (81, 97). Additionally, others have reported increases in protein 
content of AMPD3 (47) as well as activity (7, 47) in denervation induced atrophy. 
However, reason for the upregulation of AMPD3 and its role during atrophy are 
completely unknown.   
 AMP Deaminase (AMPD) is an important energetic regulator as it helps to 
maintain high ratios of ATP/ADP/AMP and thus preserve the ΔGATP (55, 56). During 
high energy demands such as exercise, the content of AMP increases in the cell. AMPD 
removes AMP from the adenine nucleotide pool which in turn favors the forward 
direction of the adenylate kinase reaction (see equation 2). The combined actions of 
AMPD and adenylate kinase help to limit ADP accumulation and maintain the ΔGATP
4. 
The induction of AMPD3 may be a response to the increased energetic challenge of 
muscle atrophy. On the contrary, increased AMPD3 may cause an energetic challenge 
itself by creating excessive adenine nucleotide degradation.  
 
AMP Deaminase Isoforms  
 There are three different isoforms of AMP Deaminase, AMPD1, AMPD2, and 
AMPD3. However, in skeletal muscle only two isoforms are expressed. AMPD1 is the 
predominant form in muscle. AMPD3 is expressed to a lesser extent than AMPD1 but is 
highly upregulated during atrophy. AMPD2 protein is not found in skeletal muscle but is 
the predominant isoform in non-muscle tissue. The total activity of AMPD is highest in 
skeletal muscle, approximately 50-100 fold greater than non-muscle tissue.  
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 The AMP Deaminases degrade AMP to IMP (see equation 3), which is central to 
maintaining the adenylate energy charge5 (AEC) (19, 91) by limiting the accumulation of  
(5) Adenylate Energy Charge = ([ATP] + ½ [ADP]) / ([ATP) + [ADP] + [AMP]) 
AMP in the muscle. In resting muscle the AEC is normally maintained around 0.8-0.9. 
This also serves to maintain the free energy of ATP hydrolysis, ΔGATP. In fact, removal 
of AMPD1 by knockout results in drop of the AEC of approximately 25% in resting 
soleus muscles (112). 
 Both AMPD1 and AMPD3 are located in the sarcoplasm and form a tetramer 
composed of varying amounts of each isoform (45, 47, 100). The two AMPD isoforms, 1 
and 3, appear to be differentially regulated. Both have a primary binding domain within 
the C-terminal for actomyosin (86). AMPD1 localizes near the myosin ATPase and will 
bind to myosin (66). During contraction and reduced pH, AMPD1 binds to myosin and 
its activity is increased (40, 126, 127). The binding of AMPD1 to myosin occurs when 
energy demand is not balanced, such as during intense contractions, and precedes any 
significant accumulation of IMP (127). 
 Conversely, AMPD3 is more active basally and is known to bind to membranes 
rather than myosin. The membrane binding of AMPD3 has been attributed to the N-
terminal sequence (87), which has also been shown to suppress contractile filament 
binding (86).  When AMPD3 binds to the membrane there is a subsequent reduction in 
its activity (87, 111). Membrane binding of AMPD3 can be induced when pH is reduced 
(87, 141). In human erythrocytes, AMPD3 binds to the cytoplasmic side of the 
membrane with a drastic drop in activity and increase in protein stability (111).  
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 The post-translational modifications of AMPD are not well understood. Although, 
protein kinase C has been shown to phosphorylate AMPD resulting in a 3-fold decrease 
in the Km without affecting Vmax (147). An additional study by Tullson et al. has 
confirmed phosphorylation-induced alterations in AMPD kinetics. In this study treatment 
of muscle homogenates with acid phosphatase resulted in removal of negative 
cooperativity and an increased Km (151). Furthermore Ca
2+ has been shown to activate 
AMPD3 in erythrocytes through binding of calmodulin (88). 
 Interestingly, an AMPD1 nonsense mutation (C34T), which results in a truncated 
inactive peptide, is among the most common mutations in humans. Roughly 20% of the 
general Caucasian population are heterozygous of the CT, and 2% are homozygous TT 
for the AMPD1 C34T mutation (99, 104). AMP Deaminase deficiencies or mutations 
have been associated with muscle weakness (44), reduced sprint performance (43) and 
muscle cramps (39, 44), and increased perceived exertion (122). Sprint and power type 
athletes are more likely to not have the C34T mutation, implying AMPD is important for 
intense efforts (50). However, there is some inconsistency in the symptoms with 
AMPD1 mutations as some patients are asymptomatic. Hanische et al. found no 
relationship between AMPD deficiency and exertion-induced complaints in over 400 
subjects (57). Additionally, the C34T mutation did not appear to have any effect on 
exercise capacity in the elderly (109).  
 A whole body AMPD1 knockout (KO) mouse was recently generated and 
characterized, displaying no obvious difference in phenotype (1). Following 5 minutes of 
electrical stimulation of the EDL, AMPD1 knockout mice exhibit large increases in [ADP] 
and [AMP] and a significant drop in the adenylate energy charge compared to wild type 
 
 
16 
 
(WT) controls (112). The maximal tetanic force was similar between WT and AMPD1 
KO in the EDL and soleus, however, the baseline force during a fatigue protocol was 
higher in AMPD1 KO soleus muscle compared to WT (112). An AMPD3 KO mouse also 
exhibits no overtly adverse phenotype but did have elevated levels of ATP in 
erythrocytes (22). Unfortunately, measurements of muscle contractile function and 
protein degradation have not been measured in the AMPD3 knockout mice. 
 
The Role of AMPD3 in Atrophy 
 During denervation atrophy, content of AMPD1 remains steady or decreases 
slightly while AMPD3 content increases and total AMPD activity increases 34% (47). 
Traditionally AMPD is thought to help maintain energetics during high energy demand 
(55, 56, 91), hence its activation during contraction. However, the upregulation of 
AMPD3 during atrophy occurs when energy demand presumably is not as high as 
typically necessary of AMPD activity. The differential regulation of AMPD1 and AMPD3 
also suggest during atrophy there may be a greater need for basal AMPD activity as 
evidence by the increased proportion of AMPD3 to the total AMPD activity. This 
increase in AMPD3 content and AMPD activity is of interest because the energetic 
disruption, rather than maintenance, that may result from nucleotide cycling or loss of 
adenine nucleotides may be a signal to induce atrophy. Currently it is unknown if 
AMPD3 is able to exert any influence on overall protein degradation or synthesis. 
Additionally, the upregulation of AMPD3 may be in response to the energetic challenge 
of atrophy, such as the drop in the ΔGATP (29, 42, 54, 110, 140). It’s also unknown if the 
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upregulation of AMPD3 attenuates some of the loss of contractile function, such as 
increased half relaxation time, or if it contributes to contractile impairments.  
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Statement of the Problem 
 Skeletal muscle is essential for quality of life because of its critical roles in 
locomotion, respiration, and whole body metabolism. During atrophy, the loss of muscle 
mass and muscle function severely impairs the quality of life and survival rates of those 
who are affected. Currently, there is a lack of sufficient treatments for the loss of muscle 
mass or loss of muscle function during atrophy. The only known effective treatment, 
exercise, may be impossible or impractical for many who suffer from atrophy. One 
exciting potential regulator of atrophy is AMPD3, which is highly upregulated during 
several types of atrophy. In a healthy muscle AMPD is activated by high energy 
demands in order to help maintain favorable energetics. It may be the case that the 
upregulation of AMPD3 during atrophy may help to maintain muscle energetics and 
performance in a state of declining function. However, the upregulation of AMPD3 
during atrophy can present a unique energy challenge to the muscle by creating a drain 
on the total adenine nucleotide pool, which may contribute to activation of protein 
degradation. This dissertation will address some of the effects of AMPD3 upregulation 
on skeletal muscle as the role of AMPD3 during atrophy is currently unknown.  
  
 
Chapter Two 
 
AMP Deaminase 3 upregulation during skeletal muscle atrophy 
improves muscle relaxation in mouse soleus 
 
 
Abstract 
Skeletal muscle atrophy severely impairs contractile function of muscle making tasks of 
daily living more difficult and results in a loss of quality of life. The purpose of this study 
was to determine whether the upregulation of AMPD3 during atrophy improved 
relaxation time of muscle, which is sensitive to reductions in the free energy of ATP 
hydrolysis, during intense contractions. AMPD3 was knocked down by RNAi during 
denervation-induced atrophy or overexpressed in the mouse soleus. Following one 
week of denervation or overexpression, soleus muscles were removed and electrically 
stimulated and contractile function measured. One week of denervation resulted in a 
20% loss of mass and an increase in AMPD3 protein expression of 67%. Knockdown of 
AMPD3 during denervation reduced AMPD3 by 60%. Denervation reduced AMPD1 
protein expression by 36%. Half relaxation time in denervated muscles is shorter during 
high intensity fatiguing contractions. Knock down of AMPD3 in denervated muscles 
resulted in a 33% increase in half relaxation time during high intensity contractions. 
Denervation increased tetanic half relaxation time from 0.041 to 0.049 ms and 
knockdown of AMPD3 further increased half relaxation time to 0.054 ms. SERCA1 and 
SERCA2 protein content were not different with denervation or knockdown. Low 
intensity contractions did not alter half relaxation time of the soleus muscles nor did 
overexpression of AMPD3 in non-atrophying muscles. Our results suggest that the 
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upregulation of AMPD3 during skeletal muscle atrophy improves muscle relaxation 
during high intensity fatiguing contractions. AMPD3 may attenuate some of the loss of 
muscle power and performance common to atrophy. 
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Introduction 
Skeletal muscle atrophy is common to many different disease states such as 
cancer, renal failure, and diabetes as well as during starvation, disuse, and denervation. 
During skeletal muscle atrophy, muscle function and power are dramatically impaired, 
making tasks of daily living more difficult (73), increases risk of falls in the elderly (103), 
and results in a loss of quality of life (137). Most notably, maximal force is reduced, 
which can be largely attributed to the overall loss of muscle mass/cross sectional area 
(2, 5, 123). However, other impairments are evident. For example, in cancer cachexia 
and denervation induced atrophy, specific force (2, 65, 102), half relaxation time (2, 53, 
65, 116), and time to peak force (53, 123) are also impaired, all of which contribute to 
reduced muscle power output. The mechanisms that account for these impairments 
during atrophy are currently unknown.  
A possible explanation of impaired contractile characteristics may be the 
depressed energetic profile of atrophy. For example, during several types of atrophy 
there is a net loss of [ATP] (33, 46, 92, 140), increased [ADP] (110), reduced free 
energy of ATP hydrolysis (ΔGATP) (29, 42, 54, 77, 110), and a loss of phosphocreatine 
(CP) (110, 140) and creatine (140). These energetic deficits are found in healthy, albeit 
atrophying, muscles that have reached a new steady-state phenotype. Furthermore, a 
number of the contractile characteristics have been shown to be sensitive to 
perturbations in energetics. For example, half relaxation time is greater in the presence 
of increased [ADP] and reduced ΔGATP (56). Additionally, high levels of [ADP] can slow 
cross bridge cycling and the time to peak force (30). Elevated levels of Pi have been 
shown to reduce the peak force and power in skinned fibers (37, 105). It is therefore 
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reasonable to suspect that energetics may play a factor in some of the contractile 
impairments observed during atrophy.  
Skeletal muscle maintains favorable energetics during high energy demands, 
when ATP consumption outpaces ATP production, by the concerted actions of 
adenylate kinase (AK: ADP + ADP → ATP + AMP) and AMP Deaminase (40, 91). 
Removal of AMP by AMP Deaminase (AMPD: AMP + H2O → IMP + NH3) favors ADP 
clearance and ATP production by AK. Taken together, these enzymes preserve the 
ΔGATP because they limit ADP accumulation and promote ATP production. However, 
the cost of sustained AMPD activity is an overall loss of adenine nucleotides, which can 
be resynthesized only during recovery (16, 150). During skeletal muscle atrophy, 
AMPD, specifically isoform 3 (AMPD3), is highly upregulated (47, 81, 97), while AMPD1 
content remains stable, and results in an increase in total AMPD activity (47). Currently 
the effects of AMPD3 upregulation during atrophy on muscle function are unknown. 
In the present study, we sought to investigate the role of increased expression of 
AMPD3 on energetics and contractile characteristics of skeletal muscle during atrophy. 
We used short hairpin RNA (shRNA) to knockdown AMPD3 protein in mouse soleus 
muscle during denervation-induced atrophy. Because of the increased AMPD activity 
during atrophy and the importance of AMPD activity in maintaining the ΔGATP, we 
hypothesized that knockdown of AMPD3 during atrophy would result in impairments of 
muscle half relaxation time which is sensitive to the ΔGATP. 
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Methods 
Expression Plasmid and shRNA Generation 
Plasmid encoding mouse AMPD3 was purchased from Open Biosystems and 
subcloned into the CMV driven pIRES-hrGFP II vector (Agilent Technologies). The 
empty pIRES-hrGFP II vector was used as a control. To knockdown AMPD3 protein, we 
designed three different shRNA oligos against mouse AMPD3 (Table 1) using 
Invitrogen’s web based RNAi designer 
(https://rnaidesigner.lifetechnologies.com/rnaiexpress/) and inserted them into pcDNA 
6.2-GW/EmGFP-miR vector using Invitrogen’s BLOCK-iT RNAi Expression Vector Kit 
with EmGFP. A negative control plasmid (shNEG) containing a hairpin forming 
sequence that is designed to not target any vertebrate genes (5’-
GAAATGTACTGCGCGTGGAGACGTTTTGGCCACTGACTGACGTCTCCACGCAGTA
CATT-3’) was provided with the kit and was used as a negative control. To test the 
efficacy of the knockdown, each plasmid was transfected into C2C12 myoblasts using 
FuGene 6 (Promega). mRNA was extracted with Trizol Reagent (Thermo Fischer) and 
real time PCR done for AMPD3 normalized to RPLPO using SybrGreen (Thermo 
Fischer). The shRNA plasmid with the greatest knockdown effect was used in all 
subsequent experiments (shAMPD3).  
Animal Procedures 
Adult male CD-1 mice were purchased from Charles River (Raleigh, NC) and 
housed in Association for Assessment and Accreditation of Laboratory Animal Care 
approved housing. Mice were approximately 30 grams at the time of muscle collection. 
They were housed 4 mice per cage, and given free access to food and water and a 12 
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hr light/dark cycle. All animal procedures were approved by the East Carolina University 
Animal Care and Use Committee.  
Expression or shRNA plasmids were transferred into skeletal muscle by 
electroporation, as done previously (14). In brief, mice were anesthetized with isoflurane 
(2-3%) in oxygen and an incision was made in the anterior lower hind limb allowing 
access to the soleus muscle. Plasmid DNA (0.5 µg/µl knockdown plasmids, 1.0 µg/µl 
overexpression plasmids) was injected lengthwise into the soleus (10 µl), using a 
Hamilton microliter syringe. Electrical pulses were applied using BTX ECM 830 
electroporator (Holliston, MA) as the muscle was sandwiched between two opposing 
stainless steel paddles (10 volts, 5x20 ms pulses at 250 ms intervals). Incisions were 
closed with Vicryl (polyglactin 910) sutures.  
Atrophy was induced by sciatic nerve sectioning as done previously at the same 
time as electroporation (14). An incision was made in the lateral mid-thigh of the hind 
limb. The sciatic nerve was exposed by blunt dissection and a 2-3 mm section was 
removed. Sham operation on the contralateral limb was done to expose the sciatic 
nerve without sectioning the nerve. The incisions were closed with surgical glue, and 
buprenex (0.03 mg/kg body weight) was administered sub-cutaneously as a post-
operative analgesic. 
Muscle Contraction 
Mice were anesthetized with isoflurane and euthanized by cervical dislocation. 
The proximal and distal tendons of soleus muscles were ligated with 2.0 silk sutures 
and placed in oxygenated (95% O2, 5% CO2) Krebs-Henseleit bicarbonate buffer (25 
mM NaHCO3, 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4•7H2O, 1.2 mM KH2PO4, 1.2 
 
 
25 
 
mM CaCl2•2H2O, 5 mM glucose, 0.15 mM sodium pyruvate) at their approximate in vivo 
resting length. Muscles were maintained in the Krebs-Henseleit buffer at 37°C for 
approximately 40 minutes prior to contractile measurements.  
Muscles were secured to a dual mode force transducer (Aurora Scientific) and 
field-stimulated via platinum electrodes (Aurora Scientific). Optimal length was 
determined using 0.3 ms pulses and the length tension relationship. Following another 
5-10 minute rest period, muscles were either subjected to a high intensity (150 Hz pulse 
frequency, 500 ms train duration, 1 train per second, for 60 seconds) or low intensity (50 
Hz pulse frequency, 250 ms train duration, 1 train every 2 seconds, for 600 sec) 
contraction protocol using 610A DMC v5.4 (Aurora Scientific) or kept at their resting 
length for approximately 5 additional minutes. Muscles were then rapidly cut from 
sutures, blotted dry, and snap frozen between liquid nitrogen cooled tongs. Contraction 
characteristics were analyzed using 611A DMA software v5.2 (Aurora Scientific). Each 
contraction was analyzed individually using the high throughput feature. For 
measurements of half relaxation time, the window for analysis was set to start with the 
last electrical pulse of each stimulation train and end just prior to the next stimulation. 
Force-time integral is the area under the force-time curve for each contraction. 
 Protein Analysis 
Muscles were homogenized using Bio-Gen PRO200 Homogenizer (Pro 
Scientific, Oxford, CT) and proteins extracted in a RIPA Buffer (1% NP-40, 0.5% 
Sodium Deoxycholate, 0.1% SDS, 50 mM Tris-HCl, 50 mM NaF, 5 mM Sodium 
Pyrophosphate, 2 mM Sodium Orthovanate) containing a protease inhibitor cocktail 
(Roche Complete). Total protein content was determined by BCA assay (Pierce) using 
 
 
26 
 
bovine serum albumin as a standard. Equal amount of protein were separated by SDS-
polyacrylamide gel electrophoresis then transferred to polyvinylidene difluoride (PVDF) 
membranes. Equal loading and even transfer were confirmed by Ponceau S staining of 
membranes.  Antibodies were purchased from abcam (AMPD3: ab118230, SERCA2: 
ab3625), Thermo Scientific (AMPD1: PA5-23172) and the Developmental Studies 
Hybridoma Bank (SERCA1: CaF2-5D2). Secondary antibodies conjugated to HRP (Cell 
signaling-7074S, Thermo Scientific-31441) were used and identified using Western 
Chemiluminesce HRP Substrate from EMD Millipore. Band intensities were captured 
using a Bio-Rad Chemi Doc XRS imager and analyzed using Image Lab software (Bio-
Rad) with weights calculated from Pageruler Plus protein ladder (ThermoFisher). 
Nucleotide Measurements 
Nucleotides were extracted from muscles by homogenization (glass-on-glass) in 
ice-cold 0.5 N perchloric acid. Extracts were neutralized by addition of ice-cold KOH and 
centrifugation at 4°C. Samples were stored at -80°C until analysis. The concentration of 
adenine nucleotides (ATP, ADP, AMP) and degradation products (IMP, adenine, and 
inosine) were determined by ultra-performance liquid chromatography (UPLC) using a 
Waters Acquity UPLC H-Class system as done previously (15). 
Statistical Analysis 
 All data are expressed as mean ± standard error of the mean. Significant 
differences were assessed using repeated measures two-way ANOVA (for comparisons 
including muscle fatigue protocols and protein content), two-way ANOVA (for 
comparisons of tetanic contraction characteristics and nucleotides), one-way ANOVA 
(for comparisons of rates of fatigue), and t-test (for comparing AMPD3 overexpression, 
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max force and half RT). If significance was detected by ANOVA, Sidak or Tukey’s post 
hoc analysis was used for multiple comparisons. All analyses were performed using 
GraphPad Prism for Windows, version 6.05 with the alpha level set at p<0.05 to detect 
significance. 
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Results 
Knockdown of AMPD3 during denervation atrophy.  
Three different plasmids were initially tested for knockdown of AMPD3 (Table 
2.1). Protein degradation was induced in cultured C2C12 myoblasts by serum 
starvation, as done previously (13), which increased AMPD3 mRNA expression by 3.3 
fold (Figure 2.1). shRNA plasmid A had no effect on AMPD3 mRNA. However, plasmid 
B prevented the serum starvation induced increase in AMPD3 mRNA (p<0.01) but did 
not knock AMPD3 down basally. Plasmid C had the best knockdown effect with a 
significant main effect of AMPD3 knock down and was used in all subsequent 
experiments (hereafter referred to as shAMPD3).  
To determine the extent by which our knockdown plasmid (shAMPD3) can 
decrease AMPD3 in adult muscles, soleus muscles were electroporated with shNEG or 
shAMPD3 at the same time as sciatic nerve sectioning. One week after 
denervation/electroporation, the AMPD3 protein content was significantly less in 
muscles treated with shAMPD3 compared to those treated with shNEG (p<0.01 main 
effect) (Figure 2.2A). Tukey corrected multiple comparisons showed significant 
differences between shAMP3 and shNEG in denervated legs. Knockdown of AMPD3 
did not affect AMPD1 protein levels but AMPD1 protein content was reduced during 
atrophy (p<0.05) (Figure 2.2B), which supports other findings that there appears to be a 
shift in the ratio of AMPD isoforms from AMPD1 to AMPD3 during atrophy (47).  
Denervation results in a complete loss of motor control of the lower limb muscles 
and represents a severe type of inactivity. One week of denervation resulted in a 
significant loss of muscle mass in the soleus (p<0.0001) compared to the innervated 
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muscle (Figure 2.2D). There was a 22% loss of muscle mass in shNEG solei and a 19% 
loss of muscle mass in shAMPD3 solei but there was no significant difference between 
shNEG and shAMPD3. 
Adenine Nucleotides.  
AMPD degrades AMP (AMP + H2O → IMP + NH3) and thereby functions as a 
regulator of the total adenine nucleotide pool (ATP + ADP + AMP) (132, 152). To 
determine if a reduced amount of AMPD3 may alter the adenine nucleotide pool in 
resting muscle, we measured the concentration of adenine nucleotides (ATP, ADP, and 
AMP) and degradation products (IMP and adenine) in homogenates of muscles that 
were collected in the resting/pre-contracted state. There were no significant differences 
detected in metabolites between innervated and denervated muscles nor was there any 
effect of AMPD3 knockdown (Table 2.2). However, there was a trend of reduced [ATP] 
in shAMPD3:Innervated. 
Characteristics of Single Tetanic Contractions.  
To determine whether AMPD3 affects contractile characteristics, soleus muscles 
electroporated with shAMPD3 were isolated and electrically stimulated in vitro. In 
response to a single tetanic contraction, muscles with knockdown of AMPD3 produced 
significantly greater max force (p<0.05) (Figure 2.3A). However, the differences in force 
output were eliminated when normalized to muscle mass i.e., the specific force did not 
differ between groups (Figure 2.3B). The half relaxation time (Figure 2.3C) was 
significantly longer in denervated muscles (p<0.0001 main effect) as well as in muscles 
that had AMPD3 knocked down (p<0.05 main effect). Between the two denervated 
groups, knockdown of AMPD3 significantly increased half relaxation time (p<0.05). 
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Additionally, there was a main effect of AMPD3 knockdown to increase the force-time 
integral (p<0.05) (Figure 2.3D), which is consistent with the increased force and longer 
half relaxation time. 
High Intensity Contractions. 
AMP deamination is expected to be most active during periods of high energy 
demand (126, 127). Therefore, a high intensity fatigue protocol (150 Hz pulse 
frequency, 500 ms train duration, 1 train per second, for 60 seconds) was used to 
create an energy demand that would result in AMP production and thus high levels of 
AMPD activity. Solei of all groups fatigued to approximately 25-30% of their initial force 
by 60 seconds (Figure 2.4A). A linear regression for each group was calculated from 5-
15 seconds to determine the rate of fatigue. These time points were chosen because 
force was decreasing in all groups after 5 seconds and there was a visual inflection 
point around 15 seconds in both denervated groups. The rate of fatigue (Figure 2.4B) 
was greater in the denervated muscles compared to the innervated (p<0.001 main 
effect). Between the two knockdown groups, the denervated muscle had a significantly 
greater rate of fatigue compared to innervated (p<0.05). 
The relaxation rate of muscle is largely dependent on the ability of the 
sarcoendoplasmic reticulum calcium ATPase (SERCA) to re-sequester Ca2+ into the 
endoplasmic reticulum. SERCA can become less active when the ΔGATP is reduced (21, 
35), such as during high energy demands. Because the relationship between relaxation 
rate and the ΔGATP as well as the role of AMPD in maintaining the ΔGATP, we examined 
the half relaxation time of each contraction during the fatigue protocol. Knockdown of 
AMPD3 significantly increased half relaxation time in both the denervated and 
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innervated muscles for roughly the last 10 and 20 contractions respectively, compared 
to the innervated group (Figure 2.4C). When comparing the two denervated groups, 
knock down of AMPD3 resulted in an approximately 33% longer half relaxation time for 
each of the last 30 contractions (0.071 ms vs. 0.053 ms by 30 seconds and 0.087 ms 
vs. 0.066 ms by 60 seconds). However, there was no significant difference between the 
two knockdown groups.   
Increases in the half relaxation time might be explained by a reduced total 
SERCA protein content or by shifts between isoforms of SERCA. To test for this we 
blotted for SERCA 1 and SERCA 2 in muscle homogenates. Neither denervation nor 
knockdown of AMPD3 altered SERCA 1 or SERCA 2 protein content (Figure 2.5). 
Because SERCA activity can be altered by the energetic state of the muscle, we 
measured nucleotides in muscles immediately post-contraction. Following the high 
intensity protocol, [ATP] was significantly reduced and [IMP] was significantly increased 
(Table 2.3). The increase in [AMP] was did not reach statistical significant (p=0.059). 
However, there were no significant differences in the metabolites between innervated 
and denervated muscles nor was there any effect of AMPD3 knockdown. The 
contraction protocol was sufficiently intense to cause a loss of total adenine nucleotides. 
Low Intensity Contractions.  
During high energy demands, which fatigue muscles to 20-25% of initial force by 
60 seconds, knockdown of AMPD3 resulted in longer half relaxation times of the 
muscle, so we next tested if the same would be true during a lower energy demand. A 
low intensity fatigue protocol (50 Hz pulse frequency, 250 ms train duration, 1 train 
every 2 seconds, for 600 sec) fatigued muscles to approximately 50% of initial force by 
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600 seconds (Figure 2.6A). The rate of fatigue calculated between 10 and 200 seconds 
in the two denervated groups was significantly higher compared to both the innervated 
and shAMPD3 groups (p<0.0001) (Figure 2.6B). Rate of fatigue did not differ between 
the two innervated groups. The half relaxation time during the low intensity protocol did 
not differ significantly between groups (Figure 2.6C). Following low intensity 
contractions there was a significant increase in [IMP] (Table 2.4) in denervated muscles 
compared to innervated muscles(p<0.05), however, there was no effect of knockdown 
on IMP levels. 
Overexpression of AMPD3.  
It is unclear if the effects of AMPD3 knockdown we observed during atrophy are 
dependent on other factors associated with atrophy such as other atrogenes, or if 
AMPD3 acts independently. Therefore, we over expressed AMPD3 in non-atrophying 
soleus muscles and subjected them to the same high intensity contraction protocol as 
the atrophying muscles. Electroporation of plasmid encoding AMPD3 in solei resulted in 
a 16 fold increase in AMPD3 protein compared to electroporation of a GFP encoding 
plasmid (Figure 2.7A). Despite this increase in AMPD3 protein, there was no difference 
in tetanic maximum force or half relaxation time in GFP vs AMPD3 (Figure 2.7B,C). 
Additionally, during high intensity fatiguing contractions there was no differences in 
fatigue or half relaxation (Figure 2.7D, E). There was a significant loss of [ATP] and 
increase in [ADP], [AMP], and [IMP] following contraction (Table 2.5). However, there 
was no effect of AMPD3 overexpression on any nucleotides.   
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Discussion 
 In this study we tested the hypothesis that knockdown of AMPD3 during atrophy 
would result in impairments of muscle half relaxation time. Indeed, knockdown of 
AMPD3 in denervated soleus muscles increased half relaxation time of a single tetanic 
contraction and during high intensity fatiguing contractions while there was no change in 
SERCA. We did not detect any significant differences of AMPD3 knockdown on 
nucleotides in resting or contracted muscle, although this does not rule out transient 
changes during intense contractions. Therefore we conclude that upregulation of 
AMPD3 during atrophy improves the half relaxation time of the soleus muscle in mice.  
Atrophying muscles have an upregulation of AMPD3 and have been shown to 
have an increased half relaxation time (2, 53, 123, 158). Our study agrees with these 
previous findings (Figure 2.3C) and extends previous findings to demonstrate that half 
relaxation time actually is reduced in denervated muscle by 5 seconds of high intensity 
fatiguing contractions (Figure 2.4C). When the upregulation of AMPD3 during atrophy is 
prevented by shRNA, the half relaxation time is roughly 33% longer by the time the 
muscle fatigues to 35% of initial force. These finding indicate that the upregulation of 
AMPD3 during atrophy improves relaxation kinetics of the muscle during high intensity 
contractions.  
Muscle relaxation is dependent on Ca2+ dissociation from troponin c which will 
then cover the myosin binding site on actin and prevent cross bridge formation. Slowed 
relaxation of the muscle likely suggests that Ca2+ handling has been decelerated. For 
example, reduced activity of SERCA would prolong Ca2+ re-sequestration and lengthen 
the duration of the contraction (35). This could easily be explained by a reduction in 
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SERCA protein content, or even a shift from the fast (type 1) toward the slow (type 2) 
isoforms. Our findings with one week of denervation atrophy do not demonstrate any 
reduction in SERCA protein content or a shift between the two different isoforms, which 
agrees with the one week findings of Schulte et al. (139). Therefore, the slowing of 
relaxation cannot be explained by SERCA protein content in this study.  
A likely explanation for the slowed relaxation of muscles while AMPD3 is 
knocked down could be reduced SERCA activity due to a reduced ΔGATP, which would 
increase the Ca2+ transit time and prolong muscle relaxation. SERCA requires a large 
yield of the ΔGATP to maintain the ~1:10,000 Ca
2+ gradient across the endoplasmic 
reticulum (21, 59). Previous observations put the free energy requirement of the SERCA 
(ΔGSERCA) around 50 kJ/mol (21, 59, 80), while ΔGATP in resting muscle typically yields -
60-65kJ/mol (21, 56). This small difference in the energy requirements of SERCA and 
available energy from ATP hydrolysis highlights how important maintenance of the 
ΔGATP is to preserve normal function of the muscle. Even with small reductions in the 
ΔGATP (<5 kJ/mol), Dawson et al. saw slowed relaxation in frog skeletal muscle (35). 
Additionally, slowed relaxation has been observed in mice lacking the adenylate kinase 
enzyme during a high intensity contraction protocol with a calculated ΔGATP of -45.6 
kJ/mol (56), which is below the requirement for the SERCA pump. Knockdown of 
AMPD3 would be anticipated to reduce total AMPD activity, which during high energy 
demands would increase [AMP] content as well as [ADP] content via product inhibition 
of the AK reaction, the result would be a drop in the ΔGATP. Taken together, our results 
indicate that knockdown of AMPD3 in both innervated and denervated muscle slows 
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muscle relaxation during high intensity contractions, likely as a result of a reduced 
ΔGATP and reduced SERCA activity.  
The nucleotide measurements taken following the high intensity contraction 
protocol (Table 2.3) show a significant loss of [ATP] and increase in [IMP] indicating that 
AMPD was active during the protocol. The high intensity protocol that we utilized had a 
50% duty cycle whereas the protocol in a study by Hancock et al., that elicited a drop in 
the ΔGATP to -52 kJ/mol, had a less intense 20% duty cycle (56). While we were not able 
to calculate the ΔGATP in our muscles because the phosphocreatine peak was not 
clearly resolved, it’s likely that the ΔGATP in these muscles was substantially reduced 
below resting levels based on the measurement by Hancock et al. from a less intense 
fatigue protocol. 
The increase in half relaxation of a single tetanic contraction (Figure 2.3C) during 
atrophy is consistent with the previous literature (2, 53, 123, 158). This seems to be due 
to factors of Ca2+ handling unrelated to the energetic state of the cell, as we did not 
detect any differences in the nucleotides of the resting muscles (Table 2.2). A possible 
explanation of the increased relaxation time could be partially depolarized mitochondria 
during atrophy which have been shown to contribute to dysfunctional Ca2+ clearance 
from the sarcoplasm (159). Decreases in parvalbumin can impair Ca2+ clearance but 
this is an unlikely factor in the soleus muscle since there is little parvalbumin in type I 
fibers (60). 
The increase in AMPD3 protein we observed during denervation atrophy is 
consistent with previous findings (7, 23, 47, 81). The AMPD enzyme in muscle is made 
up of a tetramer of AMPD proteins which can vary in composition of AMPD1 and 
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AMPD3 (47, 58). The reduction in AMPD1 and increase in AMPD3 protein content we 
observed suggests a shift to a greater reliance on AMPD3 for total AMPD activity during 
atrophy and is consistent with the findings of Fortuin et al (47). Increased AMPD activity 
during atrophy could lead to excessive adenine nucleotide degradation which may result 
in a loss of adenine nucleotides. Because of this we anticipated that in the AMPD3 
overexpressing and resting denervated muscles we would observe a reduction of total 
adenine nucleotides while knockdown of AMPD3 in denervated muscles would 
attenuate this loss. Although we were not able to detect a significant loss of adenine 
nucleotides it is likely that during rest there may not be enough energy demand to 
create [AMP] in sufficient quantities for increased AMPD activity; therefore net 
degradation of the adenine nucleotide pool would not occur. This finding (Table 2.2) is 
supported by Hancock et al. who observed no change in total adenine nucleotides in AK 
knockout mice under resting conditions (56) which further suggests that AMPD may be 
most important during high energy demands.  
When energy demand was increased by electrical stimulation and muscles were 
fatigued, we did observe a loss of total adenine nucleotides and an increase in [IMP] 
(Tables 2.3, 2.4) in both the high and low intensity protocols as compared to the resting 
values, which is in agreement of the observations of others (61, 95). Following the low 
intensity fatigue protocol the loss of adenine nucleotides was greater than during the 
high intensity protocol. Additionally, [AMP] was significantly elevated following the low 
intensity protocol, whereas the increase was not significant (p=0.059) in the high 
intensity protocol. This is likely an effect of the duration of the protocol where there was 
more time for [AMP] degradation than in the short (60 second) high intensity protocol. 
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We did not see any differences in nucleotides in denervated or AMPD3 knocked down 
muscles. This was surprising as we anticipated an increased [IMP] formation and 
greater loss of adenine nucleotides in the denervated muscle (which has higher AMPD3 
content), with attenuation of these measures in the AMPD3 knockdown muscle. One 
possible explanation of why we did not see any changes in nucleotides between groups 
following fatiguing contractions is because at the time point of measurement, ATP 
supply and demand had been matched and the need for AMP deamination was 
reduced. By 60 seconds in our high intensity protocol and 10 min in our low intensity 
protocol the muscles were no longer fatiguing as indicated by maintenance of force 
production. At this point ATP consumption would have had to drop to a level that was 
met by ATP supply and the need for AMP deamination was likely minimal. In support of 
this, Hancock et al. observed in AK null mice, a transient increase in 5% relaxation time 
that returned to control levels during a high intensity fatigue protocol (56). Future studies 
will need to address the kinetics of the adenine nucleotide pool degradation during 
repeated fatiguing contractions, perhaps by 31P-NMR.   
Overexpression of AMPD3 in non-atrophying muscle had no measurable effects 
on any of the contractile characteristics (Figure 2.7) or on adenine nucleotide 
degradation (Table 2.5). It is likely that there are other factors associated with atrophy 
that are necessary to enable the AMPD3 induced improvement of muscle relaxation. 
One possible factor could be the protein IMP dehydrogenase 2 (IMPDH2) which is also 
an atrogene, and upregulated during atrophy (81, 130). IMPD2 degrades IMP, the 
product of the AMPD reaction, and would favor an increase in AMPD activity by 
reducing product inhibition. Future studies could overexpress IMPD2 along with AMPD3 
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in muscle to determine if upregulation of the two enzymes are necessary to improve 
muscle relaxation.  
In summary our results indicate that the upregulation of AMPD3 during atrophy 
leads to a shortening of muscle relaxation kinetics during high intensity contractions. 
The improvement in muscle relaxation is likely due to improved ΔGATP which is better 
able to support higher levels of SERCA activity during the high energy demand. These 
findings have implications for most if not all types of atrophy since AMPD3 is 
upregulated in many types of atrophy (81). 
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Table 2.1. Primers used to generate AMPD3 knockdown plasmids 5’ to 3’. 
A Forward TGCTGTTTACCAGGAGGCTAGCTGTAGTTTTGGCCACTGACTGACTACAGCTACTCCTGGTAAA 
A Reverse CCTGTTTACCAGGAGTAGCTGTAGTCAGTCAGTGGCCAAAACTACAGCTAGCCTCCTGGTAAAC 
B Forward TGCTGTACTCAGGCATAGCATAGGGTGTTTTGGCCACTGACTGACACCCTATGATGCCTGAGTA 
B Reverse CCTGTACTCAGGCATCATAGGGTGTCAGTCAGTGGCCAAAACACCCCTATGCTATGCCTGAGTAC 
C Forward TGCTGTTGAGATTTCTTCAGAGGCGTGTTTTGGCCACTGACTGACACGCCTCTAGAAATCTCAA 
C Reverse CCTGTTGAGATTTCTAGAGGCGTGTCAGTCAGTGGCCAAAACACGCCTCTGAAGAAATCTCAAC 
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Table 2.2. Nucleotides in resting soleus muscles 
 n ATP ADP AMP IMP Adenine TAN + IMP 
Innervated 8 3.90 ± 0.53 1.10 ± 0.15 0.040 ± 0.004 0.012 ± 0.002 0.022 ± 0.004 5.053 ± 0.683 
Denervated 7 3.45 ± 0.76 1.02 ± 0.21 0.041 ± 0.004 0.014 ± 0.003 0.020 ± 0.004 4.522 ± 0.970 
shAMPD3:Innervated  10 2.79 ± 0.28 0.87 ± 0.09 0.051 ± 0.016 0.030 ± 0.010 0.014 ± 0.002 3.739 ± 0.350 
shAMPD3:Denervated 10 4.00 ± 0.60 1.17 ± 0.17 0.049 ± 0.010 0.017 ± 0.003 0.021 ± 0.004 5.237 ± 0.779 
Values are expressed as µmol/g. Means ± SEM. TAN=Total Adenine Nucleotides 
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Table 2.3. Nucleotides in high intensity contracted soleus muscles 
Treatment n ATP* ADP AMP IMP** Adenine TAN + IMP 
Innervated 10 
2.75 ± 0.33 
(-1.15) 
1.04 ± 0.15 
(-0.06) 
0.067 ± 0.020 
(0.027) 
0.292 ± 0.099 
(0.280) 
0.017 ± 0.003 
(0.005) 
4.170 ± 0.563 
(-0.883) 
Denervated 11 
2.27 ± 0.46 
(-1.16) 
0.82 ± 0.11 
(-0.19) 
0.055 ± 0.009 
(0.015) 
0.279 ± 0.092 
(0.265) 
0.013 ± 0.001 
(0.007) 
3.477 ± 0.553 
(-1.045) 
shAMPD3:Innervated 10 
2.36 ± 0.25 
(-0.43) 
0.95 ± 0.08 
(-0.08) 
0.065 ± 0.015 
(0.014) 
0.205 ± 0.037 
(0.175) 
0.016 ± 0.003 
(-0.002) 
3.578 ± 0.357 
(-0.161) 
shAMPD3:Denervated 10 
2.60 ± 0.21 
(-1.40) 
1.14 ± 0.17 
(-0.03) 
0.067 ± 0.012 
(0.018) 
0.372 ± 0.130 
(0.355) 
0.017 ± 0.002 
(0.004) 
4.197 ± 0.474 
(-1.040) 
Values are expressed as µmol/g. Means ± SEM. TAN = Total Adenine Nucleotides. Values in ( ) indicate 
difference from resting levels (Table 2). *p<0.01, **p<0.0001 main effect from resting values.  
 
 
43 
 
 
 
 
 
 
 
 
 
 
  
Table 2.4. Nucleotides in low intensity contracted soleus muscles 
 n ATP‡ ADP† AMP‡ IMP*‡ Adenine TAN + IMP‡ 
Innervated 
9 1.77 ± 0.34 
-(2.13) 
0.77 ± 0.19 
-(0.33) 
0.074 ± 0.022 
(0.034) 
0.227 ± 0.093 
(0.215) 
0.010 ± 0.002 
-(0.012) 
2.847 ± 0.680 
-(2.206) 
Denervated 
9 1.41 ± 0.08 
-(2.04) 
0.62 ± 0.05 
-(0.4) 
0.069 ± 0.011 
(0.028) 
0.476 ± 0.093 
(0.462) 
0.009 ± 0.001 
-(0.011) 
2.582 ± 0.212 
-(1.940) 
shAMPD3:Innervated 
7 1.93 ± 0.50 
-(0.86) 
0.84 ± 0.23 
-(0.03) 
0.097 ± 0.021 
(0.046) 
0.302 ± 0.103 
(0.272) 
0.011 ± 0.003 
-(0.003) 
3.178 ± 0.833 
-(0.561) 
shAMPD3:Denervated 
7 1.76 ± 0.16 
-(2.24) 
0.76 ± 0.06 
-(0.38) 
0.097 ± 0.017 
(0.048) 
0.542 ± 0.077 
(0.525) 
0.015 ± 0.001 
-(0.006) 
3.155 ± 0.255 
-(2.082) 
Values are expressed as µmol/g. Means ± SEM. TAN=Total Adenine Nucleotides. Values in ( ) indicate 
difference from resting levels (Table 2). * p<0.05 main effect of denervation. †p<0.05 ‡p<0.001 main effect 
from resting values 
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Table 2.5. Nucleotides in high intensity contracted AMPD3 overexpressing soleus muscles 
 n ATP* ADP* AMP** IMP** Adenine TAN + IMP 
GFP Resting 7 2.55 ± 0.19 0.64 ± 0.05 0.024 ± 0.002 0.018 ± 0.004 0.017 ± 0.001 3.22 ± 0.230 
GFP Contracted  9 2.23 ± 0.13 0.82 ± 0.04 0.039 ± 0.003 0.220 ± 0.031 0.015 ± 0.001 3.308 ± 0.178 
AMPD3 Resting  5 2.57 ± 0.24 0.66 ± 0.07 0.025 ± 0.003 0.017 ± 0.002 0.017 ± 0.001 3.269 ± 0.303 
AMPD3 Contracted 10 1.99 ± 0.20 0.72 ± 0.07 0.035 ± 0.002 0.184 ± 0.026 0.016 ± 0.001 2.930 ± 0.291 
Values are expressed as µmol/g. Means ± SEM. TAN=Total Adenine Nucleotides. Main effect of contraction * 
p<0.05 ** p<0.0001 
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Figure 2.1. AMPD3 expression with shRNA transfection. C2C12 myoblasts were transfected with 3 
shRNA plasmids targeted to AMPD3 or a negative control. Culture media was replaced with serum free 
media for 18 hours to simulate atrophy and induce AMPD3 expression. Means ± SEM. n=3. ***p<0.001 
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Figure 2.2. Knockdown of AMPD3 reduces AMPD3 protein content. Mouse soleus muscles were 
electroporated with shAMPD3 or shNEG concurrent with unilateral lower limb denervation. (A) Soleus 
wet weights after 1-week of denervation (B) AMPD3 protein content relative to shNEG:Innervated. n=7 
shNEG, 8 shAMPD3 (C) AMPD1 protein content relative to shNEG:Innervated. n=7 shNEG, 8 shAMPD3 
(D) representative western blot of images of AMPD3 and AMPD1 protein expression and Ponceau S 
staining. Means ± SEM. Brackets are main effect of knockdown, bars are main effect of denervation 
*p<0.05, ****p<0.0001 
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Figure 2.3. Knockdown of AMPD3 increases max force, half relaxation time, and force-time integral. 
Contractile characteristics of the soleus in response to a single 150 Hz 500 ms electrical stimulation. (A) 
Absolute maximal tetanic force (B) specific tetanic force (C) half relaxation time (D) force-time integral 
(area under the force-time curve). Means ± SEM, Values in ( ) are n for each group. *p<0.05 main effect 
of knockdown, ****p<0.0001 main effect of denervation, †p<0.05 vs shNEG:Denervated. 
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Figure 2.4. During high intensity 
fatiguing contractions AMPD3 
knockdown increases relaxation 
time, denervation increases rate 
of fatigue. Mouse soleus muscle 
was electrically stimulated for 60 
seconds with a high intensity 
fatigue protocol (50% duty cycle, 
1 tetani per second). (A) Percent 
of initial force during high 
intensity fatigue protocol, n’s are 
given in figure legend (B) rate of 
initial fatigue as determined by 
linear regression of the fatigue 
protocol between 5-15 seconds 
(C) half relaxation time during 
high intensity fatigue protocol. 
Every other contraction plotted 
for clarity (A&C). Means ±SEM. 
**** p<0.0001 vs Innervated, 
†p<0.05 vs shAMPD3:Innervated. 
Significance of Tukey post-hoc 
multiple comparisons, a,b p<0.05 
vs Innervated, c p<0.05 vs 
shAMPD3:Denervated 
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Figure 2.5. SERCA protein content does 
not change with AMPD3 knockdown or 
denervation atrophy. Western blot 
analysis of soleus muscle homogenates 
following 1-week of denervation and 
AMPD3 knockdown or negative control (A) 
SERCA1 protein content relative to 
shNEG:Innervated (B) SERCA2a protein 
content relative to shNEG:Innervated (C) 
representative western blot images. Mean 
±SEM n=7 shNEG, 8 shAMPD3 
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 Figure 2.6. AMPD3 knockdown 
does not increase relaxation 
time during low intensity 
contractions. Mouse soleus 
muscle was electrically 
stimulated for 600 seconds with 
a low intensity fatigue protocol 
(12.5% duty cycle, 1 contraction 
every 2 seconds).  (A) Percent of 
initial force during low intensity 
fatigue protocol, n’s are given in 
figure legend (B) rate of initial 
fatigue as determined by linear 
regression of the fatigue protocol 
between 5-100 seconds (C) half 
relaxation time during low 
intensity fatigue protocol. Every 
10th contraction plotted for 
clarity (A&C). Means ±SEM. 
****p<0.0001 vs. Innervated and 
shAMPD3:Innervated, † p<0.01 
vs Denervated 
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Figure 2.7. AMPD3 overexpression alone does not alter muscle performance. Mouse soleus muscle 
was electroporated with an AMPD3 or GFP expressing plasmid for 1 week then subjected to a high 
intensity contraction protocol. (A) Relative AMPD3 protein expression in electroporated soleus muscles 
(B) Absolute maximal tetanic force (C) half relaxation time of a tetanic contraction (D) percent initial 
force during high intensity fatigue protocol, (E) half relaxation time during high intensity contractions. 
D&E every other contraction is plotted for clarity. Means ±SEM. n=16 for protein expression; n=6 for 
tetanic; for fatigue protocol n=7 GFP, n=9 AMPD3. *p<0.05 vs. GFP 
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Chapter Three 
 
AMP Deaminase 3 overexpression accelerates protein 
degradation in C2C12 myotubes 
 
Abstract 
 Protein degradation dramatically increases during skeletal muscle atrophy 
leading to a net loss of protein and muscle mass. Because AMPD3 is highly induced in 
several types of muscle atrophy, we tested the hypothesis that AMPD3 overexpression 
would reduce the total adenine nucleotide pool and activate protein degradation. In 
C2C12 myotubes AMPD3 overexpression by adenovirus resulted in an increase in total 
AMPD activity of 2-fold and 9-fold after 24 and 48 hours of infection. By 72 hours of 
AMPD3 overexpression, [ATP], [ADP], and total adenine nucleotides were reduced by 
40, 35, and 40%, [IMP] was increased, and the adenylate energy charge remained the 
same. Total and phospho AMPK were not altered over the 72 hours. The protein 
degradation rate was 38% greater than GFP controls but protein synthesis rates were 
not significantly different, resulting in a net loss of protein and loss of myotube size with 
AMPD3 overexpression. Neither the flux nor makers of the autophagy-lysosome system 
were increased. There was no increase in several subunits of the proteasome and in-
vitro proteasome activity was not increased however, total ubiquitination decreased.  
Our results suggest that AMPD3 overexpression accelerates protein degradation, likely 
by in-vivo activation of the 26s proteasome in response to reduced ATP content. 
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Introduction 
Protein degradation dramatically increases during skeletal muscle atrophy 
leading to a net loss of protein and muscle mass (14, 27, 138). The atrophy process is 
regulated, at least in part, by a coordinated transcriptional program of atrophy related 
genes (atrogenes). The atrogenes consist of approximately 130 genes that are either up 
or down regulated during several types of atrophy such as fasting, cancer cachexia, 
renal failure, diabetes, and denervation (81, 130). Many of the atrogenes, such as FoxO 
(135, 163), PGC-1a (134), Atrogin-1/MAFbx (11), JunB (117), and Bnip3 (90), have 
been identified to independently regulate protein degradation. Some of these atrogenes 
have direct effects on the protein degradation pathways, but not all atrogenes directly 
influence the degradation machinery. One of the most highly induced atrogenes (up to 
100 fold) is AMP Deaminase isoform 3 (AMPD3) (AMP + H2O → IMP + NH3). The 
degradation of AMP by AMPD helps to maintain high ratios of ATP/ADP by shifting the 
equilibrium of the adenylate kinase (AK) reaction (ADP + ADP → ATP + AMP) toward 
ATP synthesis. The combined actions of AMPD and AK support the perseveration of the 
free energy of ATP hydrolysis (ΔGATP) during high rates of ATP consumption (55, 56). 
Additionally, sustained AMPD activity can lead to a reduction of [ATP] and the total 
adenine nucleotide pool content, and thereby acts as a regulator of the adenine 
nucleotide pool (95, 96). However, it is unknown if the upregulation of AMPD3 typical of 
muscle atrophy is able to exert any influence on protein degradation.   
AMPD exists as a tetramer composed of two different isoforms in skeletal muscle 
(45, 100). AMPD1 is the predominant form, while roughly 5% of basal AMPD activity 
can be attributed to AMPD tetramers that contain at least one AMPD3 subunit (47). The 
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influence of AMPD3 is dramatically increased during atrophy when 35% of AMPD 
activity is attributed to tetramers containing AMPD3. Importantly these isoforms appear 
to be differentially regulated. AMPD1 will bind to myosin with a resultant increase in 
activity during muscle contractions and lower pH (40, 66, 126, 127). Conversely, 
AMPD3 is more active basally, but when pH is reduced, it binds to membranes (111) 
with a subsequent reduction in activity (87). The increase in AMPD3 during atrophy 
suggests a shift in the control of AMPD to a more basally active AMPD tetramer. 
Traditionally AMPD is thought to help maintain energetics (a high ATP/ADP and 
ΔGATP) during high energy demand (55, 56, 91), but it also functions as a regulator of 
the total adenine nucleotide pool. The increase in AMPD3 protein and total AMPD 
activity during atrophy is of interest because the energetic disruption, rather than 
maintenance, that may result from excessive adenine nucleotide degradation may be a 
signal that induces atrophy. The proteasome, which is the major site of protein 
degradation (124), is more active when [ATP] is reduced (89). This phenomena has 
been reported in both cardiac (49) and skeletal muscle (32), and in-vivo cell culture (69) 
as well as in isolated preparations (24, 69, 84). Importantly, the activation of the 
proteasome by the loss of [ATP] occurs within a physiological range of [ATP] (69). 
Changes in energetics such as, loss of [ATP] (33, 42, 46, 92, 140), loss of 
phosphocreatine [CP] (42, 140), reduced ATP synthesis rate (29, 140), and increased 
[ADP] (110), and increased [Pi] (42) have been reported in atrophy. Currently it is 
unknown if the upregulation of AMPD3 during atrophy helps to maintain energetics or if 
it contributes to overall protein degradation.  
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The purpose of the present study was to investigate the effects AMPD3 
overexpression in muscle on energetics and protein degradation. To investigate this we 
used adenovirus to overexpress AMPD3 or GFP in C2C12 myotubes. We tested the 
hypothesis that AMPD3 overexpression will lead to a loss of adenine nucleotides and an 
increase in the rate of protein degradation.   
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Methods 
Animal Procedures 
Adult, male C57BL/6 mice were purchased from Charles River (Raleigh,NC). All 
animal procedures were approved by the East Carolina University Animal Care and Use 
Committee. Mice were housed 4 per cage in housing approved by Association for 
Assessment and Accreditation of Laboratory Animal Care and provided ad libitum 
access to standard chow and water. Atrophy of the lower hind limb muscles was 
induced between 7-9 weeks of age (approx. 30g) by unilateral sciatic nerve sectioning 
(denervation), as done previously (14). 5-14 days later mice were anesthetized by an 
intraperitoneal injection of ketamine:xylazine (100:10 mg/kg) and euthanized by cervical 
dislocation. The plantaris muscle was removed, frozen in liquid nitrogen, and stored at -
80°C until analysis. Muscles were homogenized and RNA was extracted in Trizol 
Reagent (Life Technologies) using a Bio-Gen PRO200 Homogenizer (Pro Scientific, 
Oxford, CT). Real time-PCR was done for AMPD3 and normalized to RPLPO using 
SybrGreen (Thermo Fischer). 
Cell Culture 
C2C12 myoblasts were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
with 10% fetal bovine serum, penicillin (100 U/mL), and streptomycin (100 µg/mL) until 
75-90% confluent. Media was switched to DMEM with 2% horse serum and 
penicillin/streptomycin to induce differentiation into multinucleated myotubes. 
Adenovirus was used to overexpress GFP or AMPD3. Custom made adenovirus, 
serotype 5 (DE1/E3), for the co-expression of AMPD3 and GFP was purchased from 
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Vector Biolabs (Malvern, PA). The use of adenovirus allows near 100% transfection 
efficiency into myotubes, which was confirmed visually by GFP fluorescence.  
Protein Analysis 
Proteins were extracted from cells with perchloric acid (PCA) or RIPA buffer and 
were then quantified by BCA Assay (Pierce). Equal amounts of protein were separated 
by SDS-PAGE (5-15% polyacrylamide, depending on target) then transferred to 
polyvinylidene difluoride (PVDF) membranes. Equal loading and transfer were 
confirmed by Ponceau S staining. Primary antibodies were purchased from ABCAM 
(AMPD3; ab118230), ThermoFisher (AMPD1; PA-23172), Enzo (19s Rpt6 PW9265; 
19s Rpt5 PW8770; 20s β5 PW8895; Ubiquitin PW8810), Cell Signaling (AMPKα #5831; 
P-AMPK #2531; LC3B #3868; ULK1 #8054; P-ULK1 #5869), and Developmental 
Studies Hybridoma Bank (MHC A4.1025). Secondary antibodies conjugated to HRP 
(Cell Signaling #7074, ThermoFisher #31444) were used and visualized with Western 
Chemiluminesence HRP Substrate (EMD Millipore). Band intensities were captured 
using a Bio-Rad Chemi Doc XRS imager and analyzed using Image Lab Software (Bio-
Rad) with weights calculated from Pageruler Plus protein ladder (ThermoFisher)..  
Degradation of Long-lived Proteins 
Degradation rate of long-lived proteins was determined from the release of the 
essential amino acid tyrosine as previously described (12, 14). On day 4 of 
differentiation, proteins were radiolabeled with L-[3,5-3H]-tyrosine (5 µCi/mL) for 24 
hours. After radio-labeling, cells were incubated with 2mM non-radioactive tyrosine for 
one hour, then repeated for another hour, in order to wash out and prevent re-
incorporation of L-[3,5-3H]-tyrosine into the cell proteome as well as to allow for the 
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breakdown of short-lived proteins. Cells were then infected with either GFP or AMPD3 
adenovirus in media containing 2mM non-radioactive tyrosine (time 0). Samples of the 
media were taken at 18, 20, 22, 24, and 30 hours. The experiment was repeated two 
other times with media samples being taken between 24 and 72 hours. Trichloroacetic 
acid (TCA) was added to media samples to 10% final concentration in order to 
precipitate proteins. Following final time point, media was completely removed and 
C2C12 myotubes were solubilized in 0.2 N NaOH. Radioactivity was measured in the 
TCA soluble supernatants and in myotubes. The rate of protein degradation was 
calculated as the mean slope of the regression lines calculated between 24-30 hours. 
Protein Synthesis 
C2C12 myotubes were infected with either GFP or AMPD3 adenovirus for 24, 48, or 72. 
On day 7 of differentiation, myotubes were pulsed with L-[3,5-3H]-tyrosine for two hours 
then washed twice with phosphate buffered saline (PBS). Proteins were precipitated 
with 10% TCA and pelleted by centrifugation. Protein pellets were re-suspended in 0.1 
N NaOH for total protein measurement by BCA (Pierce). Radioactivity was measured in 
a scintillation counter and the protein synthesis rate was calculated and normalized to 
total protein content.  
Nucleotide Measurements 
Nucleotides were extracted from C2C12 myotubes in ice cold 0.5 N PCA. Cells 
were lysed by sonication, and protein was pelleted by centrifugation. Protein pellets 
were re-suspended in 0.2 N NaOH for protein estimation by BCA Assay (Pierce). 
Supernatants were neutralized by the addition of ice cold 1 N KOH and centrifugation at 
4°C. Samples were stored at -80°C until analysis. Adenine nucleotide concentrations 
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(ATP, ADP, AMP) and degradation products (IMP, adenine, and inosine) were 
determined by ultra-performance liquid chromatography (UPLC) using a Waters Acquity 
UPLC H-Class system and a Acquity UPLC HSS T3 1.8 µm, 2.1 mm X 150 mm column 
(Waters) as done previously (15). The adenylate energy charge (AEC) was calculated 
as the mole fraction of ATP plus 0.5 the mole fraction of ADP as described by Atkinson 
(6).  
[(ATP) + 0.5(ADP)] / [(ATP) + (ADP) + (AMP)] 
AMPD Activity 
Total AMPD activity was determined by the formation of IMP in cell homogenates 
as done previously (128).  Myotubes were collected using cell lifters in a 
homogenization buffer (100 mM KCl, 50 mM Imidazole, 1 mM DTT, pH 7.0) and lysed in 
a Dounce Homogenizer. Homogenates were added to reaction buffer (150 mM KCl, 50 
mM Imidazole, 10 mM AMP, pH 7.0, 30°C) to start the reaction. Fractions of the 
reaction mixture were removed after 2, 5, and 10 minutes and enzymatic activity was 
inhibited by addition of 0.5 N PCA followed by neutralization with 1.0 N KOH. IMP was 
measured in supernatants by UPLC. AMPD activity was calculated by the rate of IMP 
formation and normalized to total protein content.  
Myotube Area 
Myotube area was quantified by analyzing the amount of myosin heavy chain 
coverage as done previously (12). In brief, after 72 hours of AMPD3 or GFP 
overexpression, myotubes were washed in a cytoskeletal stabilizing buffer (CSB) (80 
mM PIPES, 5 mM EGTA, 1mM MgCl2, 40 g/L PEG 35,000, pH 7.4), fixed with 4% PFA 
in CSB, permeabilized with 0.2% triton X-100 in CSB, and blocked with goat serum. 
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Primary antibody, which detects all isoforms of myosin heavy chain, (#A4.1025; DHSB, 
U Iowa) incubation was done overnight at 4°C followed by secondary antibody 
(AlexaFluor 647) incubation at room temperature for 1 hour. Nuclei were stained with 
DAPI and cells were imaged using a 10x objective. Ten images, from evenly distributed 
regions, in each well of a 6-well plate were captured. A total of 6 wells (60 images) were 
imaged for each condition. Images were split to individual components and converted to 
threshold images using ImageJ64 (NIH). The area representing myosin heavy chain 
and number of nuclei were measured from the threshold images.  
Autophagy Flux 
The flux through autophagy was estimated by the accumulation of LC3 II in 
myotubes (79). C2C12 myotubes were infected with Ad.GFP or Ad.AMPD3 on day 5 of 
differentiation. On day 7 myotubes were treated with 0.1 µM Concanamycin A, a 
specific inhibitor of the lysosomal proton pump, or DMSO/vehicle for 6 hours. This 
results in an accumulation of the lipidated form of LC3 (LC3 II) which is proportional to 
the rate of autophagy (145). Following concanamycin A treatment, proteins were 
collected in RIPA buffer and LC3 I and LC3 II were identified by western blot as 
described above. 
Proteasome Activity 
Activity of the chymotrypsin-like site of the proteasome was measured as 
described by Kisselev and Goldberg (12, 78) using the flurogenic peptide substrate Suc-
LLVY-AMC (Bachem; Bubendorf, Switzerland). In brief, myotubes were lifted from 
plates with trypsin-EDTA and centrifuged in 1.7 mL Eppendorf tubes. Cell pellets were 
re-suspended and permeabilized in a cytosolic extraction buffer (50 mM Tris-HCl, 250 
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mM Sucrose, 5 mM MgCl2, 0.5 mM EDTA, 1 mM DTT, 2 mM ATP, 0.025% Digitonin) 
then centrifuged again. The supernatant containing the cytosolic extract was added to 
10 volumes of proteasome activity buffer (50 mM Tris-HCl, 40 mM KCl, 5 mM MgCl2, 1 
mM DTT, 0.5 mM ATP, 0.05 mg/mL BSA) along with Suc-LLVY-AMC (100 µM final) in a 
black 96-well plate. Samples were excited at 380 nm and absorbance was measured at 
460 nm over 15 min. Results were normalized to total protein content (DC protein 
assay, Bio-Rad).  
Statistics 
All data are expressed as mean ± standard error of the mean. Significant 
differences were assessed using two-way ANOVA (for comparisons of AMPD Activity, 
% degraded, protein synthesis, LC3 I and II, and proteasome subunits) with Sidak post 
hoc analysis for multiple comparisons if significance was detected. One-way ANOVA 
was used for comparisons of nucleotides, mRNA, ULK1, and AMPK with a Bonferroni 
post hoc analysis for multiple comparisons if significance was detected. Unpaired 
student t-tests were used for comparisons of degradation rate, total protein, myotube 
size, ubiquitin, and proteasome activity. All analyses were performed using GraphPad 
Prism for Windows, version 6.05 with the alpha level set at p<0.05 to detect significance 
  
 
 
62 
 
Results 
Upregulation of AMPD3 precedes loss of mass. 
Previous studies have shown that the atrophy-induced upregulation of AMPD 
activity by AMPD3 occurs rapidly, within 36 hours of denervation (47). To examine the 
relationship between AMPD3 upregulation and muscle mass we measured both in 5 
and 14 day denervated mouse muscles. After 5 days of denervation there was no 
change in muscle mass (Figure 3.1A) while AMPD3 was upregulated 10-fold (Figure 
3.1B). AMPD3 mRNA remained elevated (8-fold) after 14 days of denervation and 
plantaris muscle had atrophied 23%. Inosine monophosphate dehydrogenase 2 
(IMPDH2), which degrades a product of the AMPD reaction (IMP), was upregulated 1.5-
fold after 14 days of denervation (Figure 3.1C). The upregulation of AMPD3 mRNA 
occurs prior to any loss of muscle mass. 
AMPD3 overexpression increases protein and activity. 
 Overexpression of AMPD3 by adenoviral delivery resulted in a time dependent 
increase in AMPD3 protein (Figure 3.2A). AMPD1 content was below detection limits 
until 48 hours. Neither AMPD3 nor AMPD1 were detectable at time 0 (Figure 3.2A). 
AMPD3 overexpression resulted in increased total AMPD activity of nearly 2-fold over 
GFP control by 24 hours and 8.6-fold by 48 hours (Figure 3.2B).  
AMPD3 degrades the total adenine nucleotide pool but does not activate AMPK. 
 To determine how AMPD3 overexpression affected nucleotide levels over time, 
adenine nucleotides and IMP were measured at several time points post AMPD3 
infection. [ATP] and [ADP] progressively declined 40% and 35% respectively, over 72 
hours (Figure 3.3A-B). [AMP] was reduced 25% by 72 hours but was not statistically 
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significant (Figure 3.3C). [IMP] was increased at 36 and 72 hours post-infection (Figure 
3.3D).  The total adenine nucleotide pool (TAN; ATP+ADP+AMP) was 40% smaller by 
72 hours of AMPD3 overexpression (Figure 3.3E), which highlights the role of AMPD in 
regulating the size of the TAN pool. The adenylate energy charge, ATP/ADP ratio, and 
ATP/AMP ratio, all of which are indicative of the ΔGATP, did not change over the time 
course of infection (Figure 3.3F-H). Consistent with a constant ATP/AMP ratio and 
adenylate energy charge, neither total AMPK nor Thr172 phosphorylation were not 
altered (Figure 3.4).  
Protein degradation is accelerated. 
 AMPD3 overexpression resulted in greater amounts of degraded protein by 18 
hours (Figure 3.5A). By 30 hours 42.4% of protein was degraded in Ad.GFP while 
46.0% of protein was degraded in Ad.AMPD3. In repeated experiments the percent 
degraded remained significantly greater in AMPD3 infected cells out until 72 hours, the 
last time point tested (Data not shown). The protein degradation rate was calculated as 
the average slope of the regression lines for each sample between 24 and 30 hours 
because the lines were most divergent within this time frame. Protein degradation rate 
was 38% greater in AMPD3 infected myotubes compared to GFP infected control 
(Figure 3.5B).  
 Protein synthesis was determined by giving a 2 hour pulse of [3H]-tyrosine and 
measuring the incorporation of radioactivity into protein extracts from myotubes. There 
were no significant differences in protein synthesis rates between AMPD3 or GFP 
infected myotubes at any time point tested (Figure 3.5C). To determine if the increase in 
protein degradation with unchanging protein synthesis led to a net loss of total protein, 
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we quantified the total protein content from each well. The total protein content is 
significantly reduced by 16% following 72 hours of AMPD3 overexpression compared to 
GFP control (Figure 3.5D) indicating a net loss of total protein has occurred.  
Increased protein degradation reduces myotube size. 
 Skeletal muscle loses protein and becomes smaller during atrophy. To further 
investigate the observed net loss of protein on the size of myotubes, we measured 
myotube size of AMPD3 and GFP infected myotubes. Myotubes were identified by the 
presence of myosin heavy chain (Figure 3.6A). In agreement with the loss of total 
protein, AMPD3 infected myotubes were smaller than the GFP infected controls (Figure 
3.6A&B) reflecting a similar state of atrophy observed in intact skeletal muscle. There 
was no measurable difference in the total number of nuclei between AMPD3 or GFP 
infected myotubes (Figure 3.6C) indicating that there was no measurable loss of cells or 
apoptosis with AMPD3 treatment. 
Autophagy flux is not altered with AMPD3 overexpression. 
 Protein degradation occurs through two main pathways, the autophagy/lysosome 
and ubiquitin/proteasome pathways. To account for the increased overall protein 
degradation, we measured the flux of autophagy by the accumulation of LC3 I and LC3 
II in myotubes treated with concanamycin A, which inhibits acidification of lysosome. 
LC3 I is cytosolic while LC3 II is lipidated and is present in the membranes of 
autophagosomes. LC3 I was increased with concanamycin A treatment but there was 
no difference between GFP and AMPD3 infected myotubes (Figure 3.7A). Likewise, 
there was significant accumulation of LC3 II with concanamycin A but no difference 
between AMPD3 and GFP infected cells. The ratio of LC3 II to LC3 I was not different 
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between GFP and AMPD3 in concanamycin A treated myotubes (Figure 3.7A). 
Therefore, the estimated flux through autophagy was not increased with AMPD3 
overexpression. 
ULK1, which phosphorylates Beclin-1 and is necessary for autophagy (129), did 
not change with AMPD3 overexpression (Figure 3.7B). The AMPK phosphorylation site 
on ULK1, Ser555, was less phosphorylated following AMPD3 overexpression which 
tended to reduce the P-ULK1/ULK1 ratio (Figure 3.7B). These data demonstrate that 
autophagy was not increased, but may have been slightly down regulated.  
Ubiquitin-Proteasome Pathway is not upregulated. 
 Because the rate of autophagic flux was not increased by AMPD3 
overexpression, we next measured several markers of the other predominant protein 
degradation pathway, the ubiquitin-proteasome pathway. Components of the 
proteasome, namely the 19S RTP5 and RTP6 and 20S β5 subunits were not increased 
during the AMPD3 infection time course (Figure 3.8A). The 20S β5 subunit was reduced 
at 24 hours but not at any other time. The activity of the chymotrypsin-like site of the 
proteasome, determined in-vitro with a fixed [ATP] of 0.72 mM, was not different 
between GFP or AMPD3 groups (Figure 3.8B). This in-vitro assay is conducted in 
cytosolic extracts and is not dependent on ubiquitination and reflects the maximal flux 
capacity of the chymotrypsin-like site of the proteasome. The amount of total poly- and 
mono-ubiquitinated protein was reduced after 48 hours of AMPD3 overexpression 
(Figure 3.8C). 
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Discussion 
 In this study we tested the hypothesis that overexpression of AMPD3 in skeletal 
muscle would lead to a loss of adenine nucleotides and an increased rate of protein 
degradation. Indeed, when AMPD3 was overexpressed by adenovirus in C2C12 
myotubes, we observed a loss of adenine nucleotides and an increase in the protein 
degradation rate. Furthermore, the increase in protein degradation rate was sufficient to 
explain most of the observed loss of total protein. This exciting finding implicates 
AMPD3 and perhaps energetics as overall contributors to protein degradation in muscle 
atrophy.   
A likely cause of some of the energetic perturbations observed during atrophy is 
AMPD3, which is highly upregulated during most, if not all, types of atrophy (81, 97). 
AMPD has two major functions within skeletal muscle. The first is to maintain a 
favorable ATP/ADP ratio by shifting the equilibrium of the AK reaction toward ATP 
synthesis (55, 91) and the second is to regulate the size total adenine nucleotide pool 
(20, 132). In our study we observed a reduction in [ATP], [ADP], and total adenine 
nucleotides while [IMP] increased (Figure 3.3) clearly demonstrating that increased 
AMPD activity can degrade the total adenine nucleotide pool. Importantly, neither the 
adenylate energy charge, ATP/ADP, nor ATP/AMP ratios changed (Figure 3.3F-H), 
which suggests the free energy of ATP hydrolysis ΔGATP is preserved with AMPD3 
overexpression.  
During denervation atrophy, AMPD3 mRNA was significantly elevated by 5 days 
post denervation and remained elevated out to 14 days (Figure 3.1B). It is interesting to 
note that the upregulation of AMPD3 mRNA occurred prior to any significant loss of 
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muscle mass (Figure 3.1A). Additionally, IMPDH3 mRNA was upregulated by 14 days 
post denervation (Figure 3.1C) which agrees with past findings (130). In our cell culture 
model, overexpression of AMPD3 by adenovirus resulted in a time dependent increase 
in both AMPD3 protein content and AMPD activity (Figure 3.2).  
The major finding of this study is that AMPD3 overexpression accelerates overall 
protein degradation in skeletal muscle. The rate of protein degradation was 17% greater 
in AMPD3 infected myotubes compared to GFP infected controls (Figure 3.5B) while 
protein synthesis rates were not different between GFP and AMPD3 infected myotubes 
(Figure 3.5C). Using the following equation, the increased degradation rate in AMPD3 
infected cells fully accounts for the total protein loss by 72 hours where [Ao] is the 
protein content of GFP infected cells, [At] is the protein content of AMPD3 infected cells, 
k is the difference in degradation rate, and t is time.   
log ([A0] / [At]) = kt / 2.303 
It is commonly known that during skeletal muscle atrophy there is a net loss of 
proteins and muscle fibers become smaller. This finding has also been reported during 
simulated atrophy in myotubes (12). In our study AMPD3 overexpression also resulted 
in smaller myotubes than GFP (Figure 3.6). The same number of nuclei between GFP 
and AMPD3 infected myotubes suggests that AMPD3 overexpression did not result in 
detectable cell death (Figure 3.6C).  
The two major components of overall protein degradation are the ubiquitin-
proteasome system and the lysosome-autophagy system (97, 163). Because we 
detected an increase in total protein degradation, it would be expected that either or 
both the ubiquitin-proteasome or lysosome-autophagy pathways would be upregulated. 
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We therefore measured components of each of these systems to address how AMPD3 
was accelerating overall protein degradation. We treated AMPD3 and GFP infected 
myotubes with concanamycin A which inhibits the lysosomal proton pump and stops 
lysosomal dependent proteolysis. This results in an accumulation of LC3 II, the extent of  
which is dependent on the rate of autophagy (79, 82). In these samples there was no 
difference in the accumulation of LC3-I or LC3-II protein or in the ratio of LC3-II/LC3-I 
between AMPD3 and GFP infected cells, which indicates that the flux of autophagy was 
not increased with AMPD3 overexpression. Whereas increases in LC3 II or the LC3-
II/LC3-I ratio have been reported in others cases of atrophy (90, 97, 106). Additionally, 
we measured the content and phosphorylation of ULK1. There was no change in ULK1 
content following AMPD3 infection (Figure 3.7B) and phosphorylation of ULK1 at 
Ser555 decreased following infection, which further suggest that autophagy was not 
upregulated with AMPD3 overexpression. Our findings demonstrate that AMPD3 does 
not directly influence autophagy, which is commonly upregulated during atrophy (90, 97, 
106). It follows then that AMPD3 acts independently of the autophagy/lysosome 
pathway to increase protein degradation. 
We next examined the ubiquitin-proteasome system for any differences with 
AMPD3 overexpression. The protein contents of several components of the proteasome 
did not increase with AMPD3 overexpression (Figure 3.8A), suggesting that proteasome 
content was not different. Using a flurogenic peptide substrate, Suc-LLVY-AMC, that is 
specific for the chymotrypsin-like site of the proteasome (78), we measured the maximal 
flux capacity of the proteasome in cytosolic extracts. There was no difference in the 
maximal activity of the proteasome between AMDP3 and GFP infected myotubes 
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(Figure 3.8B). However, this measurement takes place in-vitro with an exogenous 
supply of ATP which masks intracellular ATP concentration across samples and 
therefore does not reflect the intracellular ATP conditions. Additionally, the Suc-LLVY-
AMC peptide does not need to be ubiquitinated in order to enter the proteasome. These 
are important distinctions to make, since reduced intracellular ATP levels have been 
shown to activate the proteasome (24, 32, 49, 69, 84) and there is a significant loss of 
[ATP] in AMPD3 infected cells (Figure 3.3A). We can calculate the mM concentration of 
[ATP] at time 0 and 72 hours to be 3.16 mM and 1.84 mM respectively with the 
assumption that water content of C2C12 myotubes to be similar to that of skeletal 
muscle (0.78 ml per g) (67) and the protein content to be 24% of total weight (16). This 
allows for comparison with the findings of Huang et al. who observed an increase in the 
activity of the 26S proteasome as [ATP] was reduced from 4 mM to 0.125 mM (69). It is 
reasonable to suspect a similar activation of the 26S proteasome in our experiments 
with a drop in [ATP] from 3.16 to 1.84 mM.  
The possible mechanism behind the increased proteasome activity with reduced 
[ATP] was proposed by Smith et al. (142) who argue that when 4 ATP molecules bind 
the 19s cap there is suboptimal joining with the 20S core. However, when only 2 ATP 
molecules bind the 19S cap it allows for a better association with the 20S core to form 
the 26S proteasome and results in maximal catalytic activity. The likelihood of ATP 
binding to the 19S cap is dependent on the concentration of ATP within the cell. We 
suspect that the reduction in [ATP] with AMPD3 overexpression decreases ATP binding 
to the 19S cap which results in a greater formation of the 26S proteasome and 
increased proteasome activity in-vivo. 
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Furthering the idea that the reduction of [ATP] activates the proteasome is our 
observation of a reduction in total ubiquitinated proteins when AMPD3 is 
overexpressed. Making the assumption that the rate of ubiquitination by the E3 ubiquitin 
ligases remains the same, while the activity of the 26s proteasome increases, we 
anticipated there would be a reduction in the amount of total ubiquitinated proteins in 
AMPD3 infected myotubes, as accelerated protein degradation would reduce the pool of 
ubiquitinated proteins.  Indeed, we did see a reduction in the amount of total 
ubiquitination in our AMPD3 infected myotubes after 48 hours of AMPD3 
overexpression (Figure 3.8C). This is in contrast to what happens during atrophy when 
total protein ubiquitination increases markedly (27, 93, 97). However, the activation of 
the atrogene profile during atrophy (81, 130) directly upregulates the major muscle 
ubiquitin ligases, Atrogin-1 (135) and MuRF (27). When we overexpress a single 
atrogene, AMPD3, the entire set of atrogenes is not expected to be activated, and any 
increases in Atrogin-1 or MuRF are not anticipated. Taken together, our results indicate 
that AMPD3 overexpression activates the proteasome but does not increase 
ubiquitination. 
In summary our results indicate that overexpression of AMPD3 in skeletal muscle 
accelerates protein degradation. Increased AMPD3 expression results in a degradation 
of the adenine nucleotide pool and ATP content while the adenylate energy charge is 
preserved.  The increase is protein degradation is likely due to activation of the 
proteasome by the reduced ATP content with AMPD3 overexpression. These findings 
are exciting in that they identify AMPD3 as a new and novel regulator of skeletal muscle 
atrophy. 
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Figure 3.1. Denervation atrophy rapidly induces AMPD3. C57BL/6 mice were denervated to induce 
atrophy of the lower hind limb muscles. Plantaris muscles were removed, weighed, and mRNA was 
extracted. (A) Plantaris % atrophy after 5- and 14-days of denervation. (B) AMPD3 mRNA expression. (C) 
IMPDH2 mRNA expression. Means ± SEM. n=10. † p<0.0001 vs 5-day. *p<0.05 vs control. **p<0.0001 vs 
control. 
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Figure 3.2. AMPD3 overexpression increases total AMPD activity. C2C12 myotubes were infected with 
GFP or AMPD3 adenovirus. Protein was extracted and AMPD activity was measured at the indicated 
time points. (A) Representative western blot images for AMPD3 and AMPD1. (B) Total AMPD activity in 
homogenates. Means ± SEM. n=6 **p<0.01 vs GFP 24 Hour. ****p<0.0001 vs GFP 48 Hour. 
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Figure 3.3. AMPD3 degrades the total adenine nucleotide pool while maintaining adenylate energy 
charge. C2C12 myotube were infected with AMPD3 adenovirus for the indicated times. Nucleotides 
were extracted on day 7 in perchloric acid and subsequently quantified by UPLC. Measurements of (A) 
ATP, (B) ADP, (C) AMP, and (D) IMP are expressed as µmol/g of total protein. (E) Total adenine 
nucleotides (ATP+ADP+AMP), (F) adenylate energy charge was calculated as the mole fraction of ATP 
plus 0.5 the mole fraction of ADP. (G) ATP/ADP ratio and (H) ATP/AMP ratio. Means ± SEM. n=5 *p<0.05 
vs time 0. **p<0.01 vs time 0. 
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Figure 3.4. Total AMPK and P-AMPK remain constant with AMPD3 overexpression. C2C12 myotube 
were infected with AMPD3 adenovirus for the indicated times and proteins were extracted on day 7. (A) 
Western blot images for P-AMPK Thr 172 and AMPKα, samples are paired at time points. Relative 
protein expression of (B) P-AMPK Thr 172, (C) AMPKα, and (D) the ratio of P-AMPK to AMPK. Means ± 
SEM. n=5 
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Figure 3.5. AMPD3 overexpression accelerates protein degradation. C2C12 myotubes were infected 
with GFP or AMPD3 adenovirus for the indicated times. (A) Degradation of long-lived proteins 
determined by the release of L-[3,5-3H]-tyrosine over time. n=6. (B) Protein degradation rate between 
24-30 hours. n=6. (C) Protein synthesis rate determined by the incorporation of L-[3,5-3H]-tyrosine over 
a two hour pulse. n=4. (D) Total protein per well of a 6-well plate following 72 hours of GFP or AMPD3 
overexpression. n=6. Means ± SEM. *p<0.05 vs GFP. ***p<0.001 vs GFP. ****p<0.0001 vs GFP. 
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Figure 3.6. Myotubes are smaller with AMPD3 overexpression. C2C12 myotubes were infected with 
GFP or AMPD3 for 72 hours following which myosin heavy chain was identified by immunofluorescence. 
Images were captured from 10 evenly dispersed regions of each well of a 6-well plate, and converted to 
threshold images using ImageJ. The area of positive pixels, representing myosin heavy chain, was 
measured and averaged for each well. Six wells were imaged in total. (A) Myotube area, (B) number of 
nuclei per image. (C) Representative images. Means ± SEM n=6 **p<0.01 vs GFP 
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Figure 3.7. AMPD3 does not upregulate Autophagy. (A) C2C12 myotubes were infected with GFP or 
AMPD3 for 48 hours then treated with concanamycin A or vehicle for 6 hours following which proteins 
were extracted and LC3 I and LC3 II was identified by western blot. Means ± SEM n=6. ****p<0.0001 vs 
vehicle. (B) ULK1 and P-ULK1 Ser555 were identified by western blot in GFP or AMPD3 treated 
myotubes. Means ± SEM n=5. **p<0.01 vs time 0. ***p<0.001 vs time 0.  
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Figure 3.8. Proteasome content is not changed with AMPD3 but total ubiquitination is decreased. (A) 
C2C12 myotubes were infected with AMPD3 adenovirus for the indicated times following which proteins 
were extracted on day 7 and proteasome subunits were quantified by western blot. n=5 *p<0.05 vs time 
0. (B) Proteasome activity was determined in cytosolic extracts after 48 hours of GFP or AMPD3 
infection. n=9 (C) Total mono- and poly-ubiquitin was determine by western blot following 48 hours of 
GFP or AMPD infection. The intensity of each lane was calculated and averaged. n=5 *p<0.05. (D) 
Representative western blot image and corresponding Ponceau S staining. Means ± SEM 
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Chapter Four 
 
Supplemental Data 
 
Methods 
 
Animal Procedures 
Adult male CD-1 mice were purchased from Charles River (Raleigh, NC) and 
housed in Association for Assessment and Accreditation of Laboratory Animal Care 
approved housing. Mice were approximately 30 grams at the time of muscle collection. 
They were housed 4 mice per cage, and given free access to food and water and a 12 
hr light/dark cycle. All animal procedures were approved by the East Carolina University 
Animal Care and Use Committee.   
Expression or shRNA plasmids were transferred into skeletal muscle by 
electroporation, as done previously (14). In brief, mice were anesthetized with isoflurane 
(2-3%) in oxygen and an incision was made in the anterior lower hind limb allowing 
access to the EDL muscle. Plasmid DNA (0.5 µg/µl knockdown plasmids, 1.0 µg/µl 
overexpression plasmids) was injected lengthwise into the EDL (10 µl), using a 
Hamilton microliter syringe. Electrical pulses were applied using BTX ECM 830 
electroporator (Holliston, MA) as the muscle was sandwiched between two opposing 
stainless steel paddles (10 volts, 5x20 ms pulses at 250 ms intervals). Incisions were 
closed with Vicryl (polyglactin 910) sutures.  
Atrophy was induced by sciatic nerve sectioning as done previously at the same 
time as electroporation (14). An incision was made in the lateral mid-thigh of the hind 
limb. The sciatic nerve was exposed by blunt dissection and a 2-3 mm section was 
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removed. Sham operation on the contralateral limb was done to expose the sciatic 
nerve without sectioning the nerve. The incisions were closed with surgical glue, and 
buprenex (0.03 mg/kg body weight) was administered sub-cutaneously as a post-
operative analgesic. 
Muscle Contraction 
Mice were anesthetized with isoflurane or ketamine:xylazine (100:10 mg/kg) and 
euthanized by cervical dislocation. The proximal and distal tendons of EDL muscles 
were ligated with 2.0 silk sutures and placed in oxygenated (95% O2, 5% CO2) Krebs-
Henseleit bicarbonate buffer (25 mM NaHCO3, 118 mM NaCl, 4.7 mM KCl, 1.2 mM 
MgSO4•7H2O, 1.2 mM KH2PO4, 1.2 mM CaCl2•2H2O, 5 mM glucose, 0.15 mM sodium 
pyruvate) at their approximate in vivo resting length. Muscles were maintained in the 
Krebs-Henseleit buffer at 37°C for approximately 40 minutes prior to contractile 
measurements. For the anesthesia testing (Figure 4.4), the pre-incubation was 
approximately five minutes. 
Muscles were secured to a dual mode force transducer (Aurora Scientific) and 
field-stimulated via platinum electrodes (Aurora Scientific). Optimal length was 
determined using 0.3 ms pulses and the length tension relationship. Following another 
5-10 minute rest period, muscles were either subjected to a high intensity (150 Hz pulse 
frequency, 500 ms train duration, 1 train per second, for 60 seconds) or low intensity (50 
Hz pulse frequency, 250 ms train duration, 1 train every 2 seconds, for 600 sec) 
contraction protocol using 610A DMC v5.4 (Aurora Scientific) or kept at their resting 
length for approximately 5 additional minutes. Muscles were then rapidly cut from 
sutures, blotted dry, and snap frozen between liquid nitrogen cooled tongs. Contraction 
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characteristics were analyzed using 611A DMA software v5.2 (Aurora Scientific). Each 
contraction was analyzed individually using the high throughput feature. For 
measurements of half relaxation time, the window for analysis was set to start with the 
last electrical pulse of each stimulation train and end just prior to the next stimulation. 
Force-time integral is the area under the force-time curve for each contraction. 
 
Cell Culture 
C2C12 myoblasts were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
with 10% fetal bovine serum (FBS), penicillin (100 U/mL), and streptomycin (100 µg/mL) 
until 75-90% confluent. Media was switched to DMEM with 2% horse serum and 
penicillin/streptomycin to induce differentiation into multinucleated myotubes. 
Adenovirus was used to overexpress GFP or AMPD3. Custom made adenovirus, 
serotype 5 (DE1/E3), for the co-expression of AMPD3 and GFP was purchased from 
Vector Biolabs (Malvern, PA). Adenoviruses infect nearly 100% of myotubes, which was 
confirmed visually here by GFP fluorescence.  
Protein Analysis 
Proteins were extracted from cells with RIPA buffer and were then quantified by 
BCA Assay (Pierce). Equal amounts of protein were separated by SDS-PAGE (8% 
polyacrylamide depending on target) then transferred to polyvinylidene difluoride 
(PVDF) membranes. Equal loading and transfer were confirmed by Ponceau S staining. 
Antibodies were purchased from Cell Signaling (FoxO1 #2880; FoxO3 #2497; P-
FoxO1/3 #9464). Secondary antibody conjugated to HRP (Cell Signaling #7074) was 
used and visualized with Western Chemiluminesence HRP Substrate (EMD Millipore). 
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Band intensities were captured using a Bio-Rad Chemi Doc XRS imager and analyzed 
using Image Lab Software (Bio-Rad). 
Nucleotide Measurements 
Nucleotides were extracted from C2C12 myotubes in ice cold 0.5 N PCA. Cells 
were lysed by sonication, and protein was pelleted by centrifugation. Protein pellets 
were re-suspended in 0.2 N NaOH for protein estimation by BCA Assay (Pierce). The 
supernatants were neutralized by the addition of ice cold 1 N KOH and centrifugation at 
4°C. Samples were stored at -80°C until analysis. Adenine nucleotide concentrations 
(ATP, ADP, AMP) and degradation products (IMP, adenine, and inosine) were 
determined by ultra-performance liquid chromatography (UPLC) using a Waters Acquity 
UPLC H-Class system and a Acquity UPLC HSS T3 1.8 µm, 2.1 mm X 150 mm column 
(Waters) as done previously (15). The adenylate energy charge was calculated as the 
mole fraction of ATP plus 0.5 the mole fraction of ADP as described by Atkinson (6). 
AMP Binding Assay 
Six day differentiated C2C12 myotubes were infected with GFP or AMPD3 
expressing adenovirus for 48 hours. Media was then switched to low glucose DMEM 
(1g/L) with 2% horse serum, and 3 µM Nigericin (an ionophore to allow for a fall in 
intracellular pH) at either pH 6.5 or 7.4 for 30 minutes. A subset of wells received low 
glucose DMEM, 2% HS, 3 µM Nigericin, and 25 mM 2-deoxyglucose (2DG) at pH 6.5 
for 0, 3, 10, or 30 minutes. A final group received low glucose DMEM, 2% HS, 3 µM 
Nigericin, and 25 mM 2DG at pH 7.4 for 30 minutes. After media treatments nucleotides 
were extracted in ice cold 0.5 N PCA and UPLC analysis was done as described above. 
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Table 4.1. Nucleotides in resting EDL muscles 
 n ATP* ADP AMP**
,
† IMP**
,
†† Adenine TAN + IMP 
Innervated 9 3.80 ± 0.16 0.71 ± 0.04 0.017 ± 0.001 0.033 ± 0.006 0.010 ± 0.001 4.559 ± 0.197 
Denervated 10 3.64 ± 0.43 0.93 ± 0.11 0.042 ± 0.011 0.168 ± 0.027 0.017 ± 0.002 4.783 ± 0.562 
shAMPD3:Innervated  10 4.01 ± 0.39 0.76 ± 0.05 0.025 ± 0.006 0.036 ± 0.006 0.011 ± 0.001 4.814 ± 0.425 
shAMPD3:Denervated 10 2.72 ± 0.32 0.71 ± 0.07 0.093 ± 0.013 0.862 ± 0.013 0.020 ± 0.008 4.377 ± 0.373 
Values are expressed as µmol/g. Means ± SEM. TAN=Total Adenine Nucleotides. Main effect of denervation 
*p<0.05, **p<0.0001, main effect of knockdown †p<0.01, ††p<0.001. 
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Table 4.2.  Nucleotides in high intensity contracted EDL muscles 
 Innervated [11] Denervated [12] 
shAMPD3: 
Innervated [10] 
shAMPD3: 
Denervated [10] 
ATP 2.87 ± 0.25 2.43 ± 0.18 2.68 ± 0.20 2.42 ± 0.18 
 (-0.93) (-1.21) (-1.33) (-0.30) 
ADP 1.02 ± 0.11 0.99 ± 0.07 1.00 ± 0.08 1.04 ± 0.09 
 (0.30) (0.06) (0.24) (0.33) 
AMP*† 0.035 ± 0.004 0.055 ± 0.005 0.045 ± 0.003 0.069 ± 0.007 
 (0.018) (0.013) (0.020) (-0.024) 
IMP 0.572 ± 0.108 0.514 ± 0.071 0.579 ± 0.095 0.563 ± 0.088 
 (0.539) (0.346) (0.543) (-0.299) 
TAN+IMP 
4.497 ± 0.442 3.983 ± 0.274 4.302 ± 0.379 4.095 ± 0.322 
(-0.062) (-0.800) (-0.512) (-0.283) 
Values are expressed as µmol/g. Means ± SEM. TAN=Total Adenine Nucleotides. Values in ( ) 
indicate difference from resting levels (Table 1). *p<0.001 main effect of denervation, †p<0.05 
main effect of knockdown. n=[ ] 
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Table 4.3. Nucleotides in low intensity contracted EDL muscles 
 n ATP** ADP* AMP* IMP Adenine TAN + IMP 
Innervated 9 2.15 ± 0.20 0.95 ± 0.09 0.062 ± 0.008 0.935 ± 0.115 0.009 ± 0.001 4.091 ± 0.393 
Denervated 10 1.55 ± 0.09 0.83 ± 0.06 0.104 ± 0.008 1.091 ± 0.105 0.020 ± 0.006 3.381 ± 0.338 
shAMPD3:Innervated 9 2.22 ± 0.25 1.00 ± 0.10 0.083 ± 0.005 0.999 ± 0.160 0.010 ± 0.001 4.297 ± 0.463 
shAMPD3:Denervated 9 1.28 ± 0.15 0.66 ± 0.07 0.096 ± 0.012 0.957 ± 0.127 0.020 ± 0.009 2.981 ± 0.315 
Values are expressed as µmol/g. Means ± SEM.  TAN=Total Adenine Nucleotides. *p<0.01, **p<0.001 main 
effect of denervation 
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Table 4.4. Nucleotides in high intensity contracted AMPD3 overexpressing EDL muscles 
 n ATP* ADP**** AMP**** IMP Adenine TAN + IMP 
GFP Resting 7 4.72 ± 0.23 0.85 ± 0.04 0.020 ± 0.001 ND 0.017 ± 0.002 5.569 ± 0.271 
GFP Contracted  9 3.79 ± 0.22 1.29 ± 0.08 0.050 ± 0.006 0.513 ± 0.076 0.014 ± 0.001 5.822 ± 0.361 
AMPD3 Resting  5 4.54 ± 0.08 0.85 ± 0.04 0.021 ± 0.005 ND 0.018 ± 0.002 5.438 ± 0.131 
AMPD3 Contracted 11 4.16 ± 0.25 1.35 ± 0.08 0.050 ± 0.004 0.486 ± 0.064 0.017 ± 0.001 6.048 ± 0.380 
Values are expressed as µmol/g, ND-Not Detectable. Means ± SEM.  TAN=Total Adenine Nucleotides. Main 
effect of contraction *p<0.05, ****p<0.0001 
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Figure 4.1. Knockdown of AMPD3 reduced AMPD3 protein content. Mouse EDL muscles were 
electroporated with shAMPD3 or shNEG concurrent with unilateral lower limb denervation. (A) EDL wet 
weights after 1-week of denervation (B) AMPD3 protein content relative to shNEG:Innervated. n=8 
shNEG, 7 shAMPD3. Means ± SEM. *p<0.05 shNEG:Denervated vs. shAMPD3:Denervated, ****p<0.0001 
main effect of denervation. 
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Figure 4.2. Denervation reduces Max Force, Specific Force, FTI, and increase Half RT. Contractile 
characteristics of the EDL in response to a single 250 Hz 160 ms electrical stimulation. (A) Absolute 
maximal tetanic force (B) specific tetanic force (C) half relaxation time (D) force-time integral (area 
under the force-time curve). Means ± SEM, Values in ( ) are n for each group. ****p<0.0001 
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Figure 4.3. Knockdown of AMPD3 does not alter contractile performance of the EDL. Mouse EDL 
muscle was electrically stimulated with a high intensity fatigue protocol (250 Hz, 160 ms, 1 tetani per 
second, 60 seconds) or a low intensity fatigue protocol (80 Hz, 300ms, 1 contraction every 2 seconds, 
300 seconds). Percent of initial force (A) and half relaxation time (B) during high intensity fatigue 
protocol. Percent of initial force (C) and half relaxation time (D) during low intensity fatigue protocol. 
Percent of initial force (E) and half relaxation time (F) in GFP or AMPD3 overexpressing EDL during high 
intensity fatigue protocol. Every other (A-B, E-F) or 5th contraction (C-D) plotted for clarity. Means ±SEM. 
n’s are indicated in ( ) in figure legends. 
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Figure 4.4. Ketamine/Xylazine reduces maximal force output. Mice were anesthetized with an 
intraperitoneal injection of Ketamine/Xylazine or inhaled isoflurane and euthanized by cervical 
dislocation. Soleus muscles were removed and stimulated once (300 Hz, 250 ms) while maximal force 
was recorded. Means ± SEM. n=4-6 per group. 
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Figure 4.5. FoxO 1 and 3 expression an phosphorylation do not change with AMPD3 overexpression. 
Western blot analysis of C2C12 myotube homogenates following 0, 24, 48, or 72 hours of AMPD3 
overexpression. Means ±SEM n=5 for all groups and time points. 
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Figure 4.6. In-vivo AMPD activity. C2C12 myotubes were infected with GFP or AMPD3 encoding 
adenovirus for 48 hours. Media was then switched to low glucose DMEM (1g/L) with 2% horse serum, 
and 3 µM nigericin at either pH 6.5 (pH 6.5) or 7.4 (pH 7.4) for 30 minutes. A subset of wells received 
low glucose DMEM, 2% HS, 3 µM nigericin, and 25 mM 2-deoxyglucose (2DG) at pH 6.5 for 0, 3, 10, or 30 
minutes (0, 3, 10, 30). A final group received low glucose DMEM, 2% HS, 3 µM Nigericin, and 25 mM 
2DG at pH 7.4 for 30 minutes (2DG 7.4). After media treatments nucleotides were extracted in ice cold 
0.5 N PCA and analyzed by UPLC. n=4  
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Chapter Five 
 
Summary and Conclusions 
 
 
Skeletal muscle atrophy is regulated, at least in part, by a coordinated 
transcriptional program of atrophy related genes termed atrogenes (81, 130). Since their 
discovery, research into the regulation, functions, and mechanisms of various individual 
atrogenes has greatly advanced the understanding of skeletal muscle atrophy. Despite 
these advances, exercise remains the only effective treatment of atrophy. The discovery 
of novel regulators of muscle atrophy is a high priority of research within the field. The 
purpose of the present project was to investigate the potential of AMPD3, one of the 
most highly upregulated atrogenes (up to 100-fold) (81, 97), to regulate muscle atrophy. 
Little research on AMPD3 within the context of muscle atrophy has been published.  
 AMPD has two known functions in skeletal muscle. The first is to provide 
maintenance of the ΔGATP during high energy demands (55, 91). The second is to 
regulate of the size of the total adenine nucleotide pool (20, 132). Interestingly during 
atrophy there are reductions in both the ΔGATP (29, 42, 54, 77, 110) and in [ATP] (46, 
140), which is the major component of the total adenine nucleotide pool. It is unknown if 
the upregulation of AMPD3 during atrophy is in response to the reduced ΔGATP, or if 
contributes to the atrophic phenotype and reduced [ATP]. In order to better understand 
the role of AMPD3 in atrophy, two independent studies were designed to answer the 
following hypotheses; 1) Knockdown of AMPD3 during atrophy will result in impairments 
of muscle half relaxation time; and 2) Overexpression of AMPD3 will reduced the 
adenine nucleotide pool and increase protein degradation.  
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 Collectively, this dissertation serves to define the role of AMPD3 upregulation 
during atrophy. Herein evidence is presented that demonstrates that; i) muscle 
contractile performance is impaired during atrophy; ii) the upregulation of AMPD3 during 
atrophy improves muscle half relaxation, iii) increased AMPD3 expression degrades the 
adenine nucleotide pool; iv) AMPD3 overexpression accelerates overall protein 
degradation; and v) the ubiquitin proteasome pathway may be activated as a result of 
AMPD3 overexpression.  
Denervation impairs contractile functions 
 First, muscle contractile performance in isolated soleus and extensor digitorum 
longus (EDL) muscles of mice were measured after one week of unilateral lower hind 
limb denervation. Surprisingly, one week of denervation atrophy did not result is a 
significantly reduced maximal force in soleus muscles (Figure 2.3A) but it did the EDL 
(Figure 4.2A). A loss of force was anticipated in the denervated muscles similar to the 
findings of Schulte et al. (139), but other groups have also reported no or little force 
reduction after only one week of denervation (92, 160). Increased half relaxation time in 
both the soleus (Figure 2.3C) and EDL (Figure 4.2C) was detected, which is consistent 
with past findings in denervation (2, 53, 139) as well as other models of atrophy (119, 
123). This seems to be due to factors of Ca2+ handling unrelated to the energetic state 
of the cell, as there were no measurable differences in the nucleotides of the resting 
muscles (Table 2.2). A possible explanation of the increased relaxation time could be 
partially depolarized mitochondria during atrophy which have been shown to contribute 
to dysfunctional Ca2+ clearance from the sarcoplasm (159). Decreases in parvalbumin 
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can impair Ca2+ clearance but this is an unlikely factor in the soleus muscle since there 
is little parvalbumin in type I fibers (60). 
This study extends the previous findings related to muscle relaxation during 
atrophy to measure half relaxation time during a 60 second high intensity fatigue 
protocol. After 5 seconds of intense contractions, half relaxation time is shorter in 
denervated soleus muscles (Figure 2.4) but not in the EDL (Figure 4.3). This decrease 
in half relaxation time is transient and by approximately 45 seconds both innervated and 
denervated muscles have the same half relaxation time. Over this 40 second window, 
where relaxation is shorter, the muscles are fatiguing which indicates ATP consumption 
may be outpacing ATP supply, a condition when AMPD activity is very important to 
maintain muscle performance. The decrease in half relaxation time during the fatigue 
protocol is likely due to the upregulation of AMPD3 during atrophy, which will be 
discussed in the next section.  
 Denervation atrophy results in an increase in the fatigability of the muscle, which 
agrees with what has been previously reported (53, 92, 131, 160). This was apparent in 
both high and low intensity fatigue protocols. The increased fatigability of the 
denervated muscle is likely in response to a reduced mitochondrial content and 
function, which has been well documented in atrophy (14, 29, 108, 156).  
AMPD3 influence on muscle contractile performance 
 Second, this study shows the role of AMPD3 during atrophy on muscle 
performance. By electroporating a shRNA plasmid targeted to AMPD3 into muscle the 
atrophy induced upregulation of AMPD3 was attenuated. This type of study design 
allowed for the determination of the specific effects of AMPD3 upregulation on muscle 
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performance. As already mentioned, denervation increases half relaxation time of a 
single tetanic contraction. Knockdown of AMPD3 combined with denervation has an 
additive effect to further increase half relaxation time only in the soleus (Figure 2.3C). It 
appears then that the upregulation of AMPD3 during atrophy attenuates increased 
muscle relaxation. 
During high intensity contractions knockdown of AMPD3 increased relaxation 
time in both innervated and denervated muscles when compared to the innervated and 
denervated controls respectively. These differences were not explained by changes in 
SERCA isoform or content. The most likely explanation for the slowed relaxation of 
muscles while AMPD3 is knocked down could be reduced SERCA activity due to a 
reduced ΔGATP, which would increase the Ca
2+ transit time and prolong muscle 
relaxation. SERCA requires a large yield of the ΔGATP to maintain the ~1:10,000 Ca
2+ 
gradient across the endoplasmic reticulum (21, 59). Previous observations put the free 
energy requirement of the SERCA (ΔGSERCA) around 50 kJ/mol (21, 59, 80), while 
ΔGATP in resting muscle typically yields -60-65kJ/mol (21, 56). This small difference in 
the energy requirements of SERCA and available energy from ATP hydrolysis highlights 
how important maintenance of the ΔGATP is to preserve normal function of the muscle. 
Even with small reductions in the ΔGATP (<5 kJ/mol), Dawson et al. saw slowed 
relaxation in frog skeletal muscle (35). Additionally, slowed relaxation has been 
observed in wild type mice during a high intensity fatigue protocol where the ΔGATP was 
-52.8 kJ/mol (56). In the adenylate kinase knockout mouse, relaxation was further 
impaired during the high intensity contraction protocol, where the calculated ΔGATP was 
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-45.6 kJ/mol (56). These previous studies clearly demonstrate the sensitivity of SERCA 
to ΔGATP and this study falls in line with those observations. 
Taken together, these results indicate that knockdown of AMPD3 in both 
innervated and denervated muscle slows muscle relaxation during high intensity 
contractions, likely as a result of a reduced ΔGATP and reduced SERCA activity. This 
seems to be somewhat inconsistent with the understanding that AMPD3 is inactivated 
with a reduced pH (86, 87, 111), such as during contraction. However, there are two 
possible explanations that could address this inconsistency. First, the affinity of AMPD1 
to bind myosin may be greater than affinity of AMPD3 to bind to membranes. This would 
suggest that any tetramers that contained AMPD1 subunits, would preferentially bind to 
myosin rather than bind to membranes. The result would be activation of AMPD1 and 
an increase in activity. The second explanation would be that AMPD3 may act as an 
AMP sink during high energy demands. In this model, during low pH, AMPD3 would 
bind to membranes with a subsequent inhibition of its catalytic ability. However, AMP 
would still to bind to AMPD3 without undergoing catalytic degradation. In this scenario, 
increased AMP binding would reduce the [AMP] and favor the forward reaction of AK 
and maintenance of the ΔGATP. This would be a favorable scenario as this would 
attenuate the loss of adenine nucleotides during high energy demands. Future studies 
would need to address the potential of AMPD3 to bind AMP without degrading it.  
 The lack of any different contractile characteristics in the EDL with AMPD3 
knockdown suggests that there is sufficient total AMPD activity from contributions of 
AMPD1, that the increase in AMPD3 does not supply additional maintenance of the 
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ΔGATP. This is supported by previous findings that the EDL has a much higher AMPD1 
content and total AMPD activity than the soleus (120).  
AMPD3 controls the size of the adenine nucleotide pool.  
ATP, ADP, and AMP can all be rapidly interconverted between each other by the 
transfer, removal, or addition of phosphate groups by ATPases, ATP synthases, 
adenylate kinase (AK), and creatine kinase. The ratio of free metabolically available 
ATP/ADP/AMP is maintained roughly around 1,000,000/1,000/1. AMPD reaction is 
important during high energy demands when the ratio of ATP/ADP/AMP is shifted 
toward AMP. Removal of AMP helps to shift this ratio back toward ATP. But the removal 
of AMP over time will decrease the total adenine nucleotide pool. Because of this, 
AMPD can exercise control over or regulate the total adenine nucleotide pool.   
Overexpression of AMPD3 in C2C12 myotubes led to a loss of [ATP], [ADP], and total 
adenine nucleotides (Figure 3.3). Additionally, there was an increase in [IMP] while the 
adenylate energy charge remained constant. These findings stand in slight contrast to 
the findings of Plaideau et al., who did not see differences in total adenine nucleotides 
when AMPD1 or AMPD2 were overexpressed in HEK 293t cells (113). However, this is 
likely because AMPD3, appears to be the most active of the three isoforms under basal 
conditions. 
All three isoforms have an actomyosin binding domain in the C-terminal while 
only AMPD1 has an N-terminal sequence that promotes binding to myosin (86). Both 
AMPD2 and AMPD3 have N-terminal sequences that suppress binding to myosin with 
AMPD3 exhibiting the stronger suppression (86, 87). AMPD1 will bind to myosin with a 
resultant increase in activity, during muscle contractions and lower pH (40, 66, 126, 
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127). Conversely, AMPD3 is more active basally but when pH is reduced, it binds to 
membranes (111) with a subsequent reduction in activity (87). Little is known about the 
regulation of AMPD2 and it isn’t expressed in skeletal muscle. The increase in AMPD3 
during atrophy suggests a shift in the control of AMPD to a more basally active AMPD 
tetramer and explains the loss of adenine nucleotides seen in this study and likely the 
loss of [ATP] in other models of atrophy (33, 42, 46, 92, 140). 
AMPD3 accelerates protein degradation. 
A very exciting finding of this study is that AMPD3 overexpression accelerates 
protein degradation. When AMPD3 was overexpressed in C2C12 myotubes the 
degradation of long-lived proteins was accelerated (figure 3.5). The increase in protein 
degradation rate resulted in, and fully accounted for a loss of total protein. In further 
support of the increased protein degradation, myotubes atrophied with AMPD3 
overexpression. This was demonstrated by smaller myotubes in AMPD3 infected cells 
(Figure 3.6). There was no change in the protein synthesis rate with AMPD3 
overexpression which is in agreement with the net loss of protein.  
Protein degradation in dominated by two different pathways, the ubiquitin-
proteasome and the autophagy-lysosome. The increase in protein degradation would 
likely result in an increase of either or both of these protein degradation pathways. 
However, the increase in total protein degradation was not explained by any change in 
estimated flux of autophagy or in ULK1 (Figure 3.7). Additionally, the content of the 
proteasome did not change with AMPD3 overexpression (Figure 3.8). The activity of the 
chymotrypsin-like site of the proteasome, determined in-vitro with a fixed [ATP] of 0.72 
mM, was not different between GFP or AMPD3 groups (Figure 3.8). This measurement 
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takes place in-vitro with an exogenous supply of ATP which masks intracellular ATP 
concentration across samples and therefore does not reflect the intracellular ATP 
conditions Additionally, the Suc-LLVY-AMC peptide does not need to be ubiquitinated in 
order to enter the proteasome. These are important distinctions to make, since reduced 
intracellular ATP levels have been shown to activate the proteasome (24, 32, 49, 69, 
84) and there is a significant loss of [ATP] in AMPD3 infected cells (Figure 3.3). This 
mechanism will be discussed in more detail in the next section.  
AMPD3 increases protein degradation by activation the 26S proteasome with reduced 
[ATP] 
AMPD3 overexpression resulted in an increase in overall protein degradation but 
no apparent change in the two major protein degradation pathways, autophagy or 
proteasome. This was somewhat puzzling as the increase in protein degradation could 
not be attributed to either of these two pathways. A search of the literature revealed that 
reduced [ATP] has been shown to activate the 26S proteasome (24, 32, 49, 69, 84). 
This may explain why the in-vitro proteasome activity assay (Figure 3.8) was unable to 
detect any differences with AMPD3 overexpression.  
The mechanism behind the increased proteasome activity with reduced [ATP] 
was proposed by Smith et al. (142) who argue that when 4 ATP molecules bind the 19s 
cap there is suboptimal joining with the 20s core. However, when only 2 ATP molecules 
bind the 19s cap it allows for a better association with the 20s core to form the 26s 
proteasome and results in maximal catalytic activity. The likelihood of ATP binding to 
the 19s cap is dependent on the concentration of ATP within the cell. The reduction in 
[ATP] with AMPD3 overexpression would be expected to decrease ATP binding to the 
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19s cap, which results in a greater formation of the 26s proteasome and increased 
proteasome activity in-vivo. 
Furthering the idea that the reduction of [ATP] activates the proteasome is the 
observation of a reduction in the ubiquitination of protein when AMPD3 is 
overexpressed. This is in contrast to what happens during atrophy, when total protein 
ubiquitination increases markedly (6, 31, 32). The activation of the entire set of 
atrogenes during atrophy (81, 130) directly upregulates the major muscle ubiquitin 
ligases, Atrogin-1 (135) and MuRF (27). When a single atrogene, AMPD3, is 
overexpressed, the entire atrogene profile is not expected to be activated, and any 
increases in Atrogin-1 or MuRF are not anticipated. This is supported by the lack of any 
increase in content or phosphorylation of the major atrophy related transcription factors 
(FoxO1 and FoxO3), with AMPD3 treatment (Figure 4.5). If the rate of ubiquitination is 
unchanged and the activity of the proteasome is increased, it follows that there would 
be a decrease in the amount of total ubiquitination. This is exactly what was observed in 
this study (Figure 3.8). These results indicate that AMPD3 overexpression activates the 
26S proteasome but does not increase ubiquitination. Future studies will need to 
address the in-vivo proteasome activity during AMPD3 overexpression to determine if 
the loss of [ATP] by AMPD3 can activate the proteasome.  
Taken together, these studies highlight the known functions of AMPD and their 
involvement in atrophy. First, AMPD helps to maintain ΔGATP during high energy 
demands. During atrophy, the upregulation of AMPD3 helps to maintain or prevent 
further reductions of the ΔGATP during intense muscle contraction. This was 
demonstrated by improved muscle relaxation kinetics when AMPD3 was upregulated 
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during atrophy and impaired relaxation kinetics when AMPD3 was knockdown during 
atrophy. The relaxation kinetics of the muscle is indicative of the ΔGATP because 
SERCA is dependent on a large ΔGATP. Secondly, AMPD3 acts as a regulator of the 
total adenine nucleotide pool. Overexpression of AMPD3 in C2C12 myotubes led to a 
loss of adenine nucleotides. This seems to be partly due to AMPD3 being more active 
under basal/resting conditions. Furthermore, the reduction of [ATP] leads to an 
activation the proteasome and increased protein degradation. These findings are 
exciting in that they identify AMPD3 as a novel regulator of skeletal muscle performance 
and protein degradation during atrophy. 
As there is currently a lack of practical treatments for skeletal muscle atrophy 
available, the identification of AMPD3, and perhaps energetics in general, as regulators 
of atrophy necessitates further investigation into treatments that could inhibit AMPD 
during atrophy. Clinically, inhibition of AMPD3 during conditions of atrophy may slow the 
rate of protein degradation and perhaps spare some muscle mass while the underlying 
cause of the atrophy is treated (i.e. cancer, injury, organ failure, etc.). The inhibition of 
AMPD3 may lead to slower muscle relaxation in slow type I fibers but not in fast type II 
fibers. This would likely be of little consequence to the quality of life of an atrophy 
patient as the need for a rapid succession of contractions is not common. On the other 
hand, inhibition of AMPD3 may improve maximal tetanic force in type I fibers which may 
be a large benefit in conditions of atrophy, where maximal force output is being lost. 
Overall, the benefits of AMPD3 inhibition during atrophy may outweigh the costs, but 
more research is necessary to fully explore the cost vs benefit balance.  
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